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ABBREVIATIONS AND CHEMICAL NAMES
Ae amount excreted in urine
AUC(0-?) area under drug concentration-time curve (time 0 to infinity)
AhR aryl hydrocarbon receptor
Arnt AhR nuclear translocator protein
Cmax peak concentration
CAR constitutive androstane receptor
CI confidence interval
Clint, in vitro in vitro intrinsic clearance
Clh estimated hepatic clearance in vivo
Clrenal renal clearance
cMOAT canalicular multispecific anion transporter (MRP2)
CV coefficient of variation
CYP cytochrome P450
DDD defined daily dose
DNA deoxyribonucleic acid
DSST Digit Symbol Substitution Test
GST glutathione-S-transferase
HLM human liver microsomes
HPLC high-performance liquid chromatography
IC50 concentration of inhibitor corresponding to a 50% decrease in
reaction velocity
ke elimination rate constant
Ki inhibition constant
MgCl2 magnesium chloride
MI metabolic intermediate
MRP multidrug resistance protein
MS multiple sclerosis
m/z mass-to-charge ratio
Na+ sodium
NADPH reduced form of nicotinamide adenine dinucleotide phosphate
NaOH sodium hydroxide
NMDA N-methyl-D-aspartate
NSAID non-steroidal anti-inflammatory drug
NTCP Na+-dependent taurocholate co-transporting polypeptide
OATP organic anion-transporting polypeptide
OC oral contraceptive
P pigment
PAH polycyclic aromatic hydrocarbon
P-gp P-glycoprotein
PM poor metaboliser
PXR pregnane X receptor
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RXR retinoid X receptor
SCI spinal cord injury
SD standard deviation
SEM standard error of the mean
SHBG sex hormone binding globulin
SNP single nucleotide polymorphism
SSRI selective serotonin reuptake inhibitor
SULT sulfotransferase
tmax time to peak concentration
t1/2 elimination half-life
UDP uridine-diphosphate
UGT UDP-glucuronosyltransferase
UM ultrarapid metaboliser
VAS visual analog scale
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ABSTRACT
Background and objectives. Tizanidine is an ?2-adrenergic agonist and a centrally-
acting skeletal muscle relaxant closely related to the antihypertensive drug
clonidine. High plasma concentrations of tizanidine are associated with several
undesirable pharmacodynamic effects, such as hypotension, drowsiness, dizziness
and dry mouth. The oral bioavailability of tizanidine has been reported to be
approximately 20% to 40% due to its extensive first-pass metabolism. The
metabolism of tizanidine is also crucial for its elimination but the cytochrome
P450 (CYP) enzymes responsible for its biotransformation have not been
identified. Only approximately 3% is excreted as unchanged tizanidine into urine.
  The aims of the present studies were to (1) investigate in vitro if tizanidine is
metabolised by CYP enzymes and to identify the CYP enzymes mainly
responsible for tizanidine elimination in order to evaluate its potential for in vivo
drug-drug interactions, and (2) investigate the effects of CYP1A2 inhibiting drugs
[fluvoxamine, ciprofloxacin and oral contraceptives (OCs)] on tizanidine
pharmacokinetics and pharmacodynamics in healthy volunteers, and (3) correlate
tizanidine pharmacokinetics with CYP1A2 activity, measured using a caffeine
test.
Methods. Study I was performed in vitro using pooled human liver microsomes
(HLM) and human recombinant CYP isoforms. Studies II and III were
randomized, double-blind, placebo-controlled cross-over studies, with 10 healthy
male volunteers in each study. Study IV was an open parallel group study with 15
healthy female volunteers using OCs and 15 healthy female control subjects. A
single 4 mg dose of tizanidine was administered after pretreatment with placebo
(Study II and III) and fluvoxamine 100 mg once daily for 4 days (Study II), or
ciprofloxacin 500 mg twice daily for 2.5 days (Study III) or during treatment with
an OC containing ethinylestradiol (20 or 30 µg) and gestodene (75 µg) or without
treatment in the controls (Study IV). In Studies II to IV, plasma concentrations and
pharmacodynamic effects of tizanidine were measured and a caffeine test, for
measuring CYP1A2 activity, was performed. Furthermore, in Study IV, the
concentrations of tizanidine and several of its metabolites (M-3, M-4, M-5, M-9
and M-10) were measured in plasma and urine.
Results. In vitro, the elimination of tizanidine by HLM was markedly inhibited by
the chemical CYP1A2 inhibitors furafylline, fluvoxamine and ciprofloxacin, but
not by inhibitors of other CYP isoforms. Of the recombinant CYP enzymes tested,
only CYP1A2 was able to considerably metabolise tizanidine.
  In humans, fluvoxamine increased the area under the plasma concentration-time
curve from time 0 to infinity [AUC(0-?)] and the peak plasma concentration
(Cmax) of tizanidine by 33-fold (P < .001) and 12-fold (P < .001), respectively,
compared to control phase values. Ciprofloxacin increased tizanidine AUC(0-?)
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and Cmax by 10-fold (P < .001) and 7-fold (P < .001), respectively, compared to
control values. On average, the AUC(0-?) of tizanidine was approximately 4
times greater (P < .001) and the Cmax approximately 3 times higher (P < .001) in
the users of OCs than in the control subjects. Fluvoxamine markedly prolonged
the elimination half-life (t1/2) of tizanidine, from 1.5 hours to 4.3 hours (P < .001).
Ciprofloxacin and the OCs had only marginal effects on the t1/2 of tizanidine. The
mean tizanidine/metabolite ratios in plasma and urine were 2 to 10 times higher in
the users of OCs than in the controls. Tizanidine pharmacokinetics and the extent
of the interactions showed considerable interindividual variations. In all three in
vivo studies, the caffeine/paraxanthine ratio correlated with tizanidine
pharmacokinetics. The pharmacodynamic effects of tizanidine were much stronger
when tizanidine was administered concomitantly with fluvoxamine, ciprofloxacin
or OCs, and the effects correlated with the plasma concentrations of tizanidine. In
particular, the blood pressure-lowering effect of tizanidine was increased by
inhibition of CYP1A2.
Conclusions. These studies demonstrate the principal role of CYP1A2 in the
metabolism of tizanidine in humans and the potentially hazardous interactions
between tizanidine and drugs inhibiting CYP1A2. Concomitant use of tizanidine
and fluvoxamine should be avoided, and care should be exercised when tizanidine
is used concomitantly with ciprofloxacin or OCs containing ethinylestradiol and
gestodene.
Introduction
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INTRODUCTION
Drug interactions can cause considerable differences in drug response and lead to
adverse effects of drugs. When several drugs are administered concurrently there
may be a possibility for drug-drug interactions. Many of the important drug-drug
interactions take place within the metabolic processes of drugs.
The major mechanism for elimination of drugs from the body is metabolism, and
CYP enzymes are crucial for the biotransformation of a great number of drugs.
They are abundantly expressed in the liver, the primary organ for drug
metabolism. However, CYP enzymes can be detected throughout the body, for
example in the wall of the small intestine (Kivistö et al. 1996, Zhang et al. 1999,
Ding & Kaminsky 2003). The three CYP enzyme families involved in human drug
metabolism are CYP1, CYP2 and CYP3 (Wrighton & Stevens 1992).
Drugs that inhibit CYP enzymes can lead to increased plasma concentrations, and
consequently increased toxicity, of certain other drugs metabolised by the CYP
enzymes. Induction of CYP enzymes can lower the plasma concentrations and
effects of drugs. On the other hand, if the substrate is a prodrug activated by CYP-
mediated metabolism, inhibition of its metabolism can reduce drug effect and
induction can enhance its effects. In recent years the knowledge of drug-drug
interactions based on metabolism has increased, together with clinical recognition
of such interactions as reasons for adverse effects or inefficacy of drug treatment.
Tizanidine is a centrally-acting skeletal muscle relaxant that has been in clinical
use for more than 20 years. Tizanidine is generally used for the symptomatic
treatment of chronic spasticity resulting from diverse neurologic disorders, of
musculoskeletal pain associated with increased muscle tension and of chronic
headache (Wagstaff & Bryson 1997, Lake & Saper 2002). The antispasticity
effects of tizanidine are mediated by its ?2-adrenergic agonistic properties. In
addition to the muscle relaxant effects, tizanidine has several other
pharmacodynamic effects, for example drowsiness, dizziness and decrease in
blood pressure, which are often undesirable.
Tizanidine has a low oral bioavailability due to extensive first-pass metabolism.
Tizanidine is mainly excreted as metabolites in urine, and only approximately 3%
is excreted as unchanged tizanidine (Tse et al. 1987, Koch et al. 1989). Therefore,
the metabolic clearance of tizanidine is crucial for its elimination.
At the time of initiation of the present work, the CYP enzymes involved in the
metabolism of tizanidine were unknown. The aim of this work was to investigate
which CYP enzymes are involved in the metabolism of tizanidine in vitro, and to
investigate the effects of CYP1A2-inhibiting drugs (fluvoxamine, ciprofloxacin
Introduction
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and OCs containing ethinylestradiol and gestodene) on tizanidine
pharmacokinetics and pharmacodynamics in healthy volunteers.
Review of the literature
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REVIEW OF THE LITERATURE
1. Drug metabolism, CYP enzymes and drug transporters
1.1. Drug metabolism
Xenobiotics, including drugs, are eliminated from the body by several different
means. Most drugs are lipophilic and need to be biotransformed into more
hydrophilic metabolites in order to be excreted into urine or bile. This
biotransformation is catalysed in humans by a number of drug-metabolising
enzymes. The metabolites are often less active than the parent drug, but sometimes
biotransformation may enhance activity or toxic effects (Meyer 1996).
The liver is the major organ for drug biotransformation (Meyer 1996), but drug-
metabolising enzymes are also present at other sites, such as the intestinal wall,
kidney, lung, and skin (Krishna & Klotz 1994). Due to the rather high expression
of some of the drug metabolising enzymes in the gastro-intestinal tract, an orally
administered drug may already be biotransformed in the absorption phase, when
passing through the intestinal wall (Back & Rogers 1987). In general, absorbed
compounds are transported to the liver by the portal circulation for subsequent
metabolism. Thus, prior to entering the systemic circulation, a drug has often been
metabolised to a notable degree. This phenomenon is called first-pass, or
presystemic, metabolism. Therefore, the amount of intact drug reaching the
systemic circulation may be low and may differ considerably compared to
intravenous administration of the same drug. In other words, drugs with a
considerable presystemic metabolism have a low oral bioavailability.
The metabolism of a drug usually takes place in two phases, termed
functionalisation (phase I) and conjugation (phase II) reactions, respectively. The
phase I reactions are mostly oxidative, incorporating a functional molecule such as
a hydroxyl (OH-) group into the drug molecule (Meyer 1996). Other types of
phase I reactions are, for example, reduction and hydrolysis (Meyer 1996). CYP
enzymes play a major role in phase I human drug metabolism. Phase II reactions
usually conjugate the drug with endogenous molecules, such as a glucuronide,
glutathione or a sulfate group. Phase II enzymes that catalyse conjugation
reactions include broad specificity transferases such as UDP-
glucuronosyltransferases (UGT), glutathione-S-transferases (GST) and
sulfotransferases (SULT).
1.2. CYP enzymes
The CYP enzymes are a superfamily of heme-containing mono-oxygenases
(Wrighton & Stevens 1992, Meyer 1996). Cytochrome P450 enzymes are so
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called because the pigment (P) has a 450 nm spectral peak when reduced and
bound to carbon monoxide (Omura & Sato 1962). Of the 18 CYP families
recognised in humans, only the first three CYP families (CYP1, CYP2 and CYP3)
seem to be important in drug metabolism (Table 1). The other CYP families are
generally involved in endogenous processes, particularly hormone biosynthesis.
CYP families are further divided into subfamilies and individual isoenzymes. The
amino acid sequences of the enzymes within each family (for example, CYP2B6
and CYP2E1) are at least 40% identical, and within each subfamily (for example,
CYP3A4 and CYP3A5) they are at least 55% identical. An individual enzyme (for
example, CYP1A2) is identified by a number following the letter for a subfamily
(Nebert & Russell 2002).
The estimated proportions of the major drug-metabolising CYP enzymes in human
liver are as follows; CYP3A4 29%, CYP2C8 19%, CYP2E1 19%, CYP1A2 16%,
CYP2C9 12%, CYP2D6 3%, CYP2C19 2%, and CYP2B6 < 1% (Pelkonen et al.
1998, Proctor et al. 2004). However, there are notable interindividual differences
in the hepatic contents of the different CYP enzymes. Furthermore, the hepatic
abundance of the CYP enzymes do not correlate with the importance of the
individual enzyme in drug metabolism. For example, CYP2D6 metabolises more
than 75 different drugs (Nebert & Russell 2002), but CYP2E1 metabolises
relatively few drugs. Examples of substrates, inhibitors and inducers of these
individual isoenzymes are presented in Table 1.
Table 1. Examples of substrates, inhibitors, and inducers of some CYP enzymes.
CYP1A2 CYP2C8 CYP2C9 CYP2C19 CYP2D6 CYP3A4
SUBSTRATES
Caffeine1 Carbamazepine9 Glibenclamide1 Citalopram15 Amitriptyline1 Alprazolam1
Clozapine1 Cerivastatin10,11 Glimepiride1 Diazepam9 Codeine1 Amiodarone1
Flutamide2 Ibuprofen9 Glipizide1 Proguanil9 Fluoxetine1 Cyclosporin1
Lidocaine3 Paclitaxel9 Ibuprofen1 Proton pump inhibitors16 Fluvoxamine1 Felodipine1
Melatonin4 Repaglinide12 Losartan1 S-mephenytoin17 Haloperidol1 HIV-protease inhibitors1
Olanzapine5 Rosiglitazone13 Phenytoin1 Metoprolol1 Lovastatin1
Ropivacaine6 Tolbutamide9 S-warfarin1 Nortriptyline1 Midazolam1
Tacrine1 Zopiclone14 Tolbutamide1 Ondansetron1 Nifedipine1
Theophylline1 Oxycodone1 Simvastatin1
Tizanidine7 Propafenone1 Tacrolimus1
Triamterene8 Tramadol1 Triazolam1
INHIBITORS
Cimetidine18 Gemfibrozil10,11 Amiodarone9 Clarithromycin22 Flecainide23 Clarithromycin1
Ciprofloxacin1 Trimethoprim20 Fluconazole1 Fluconazole1 Fluoxetine23 Erythromycin1
Fluvoxamine1 Montelukast21 Miconazole9 Fluvoxamine9 Quinidine1 Grapefruit juice25
Furafylline17 Sulfaphenazole9 Omeprazole1 Paroxetine24 HIV protease inhibitors26
Rofecoxib19 Itraconazole27
INDUCERS
Carbamazepine28 Phenobarbital30 Phenobarbital30 Phenobarbital9 Unknown23 Carbamazepine17
Charcoal grilled meat29 Rifampicin31 Rifampicin31 Rifampicin31 Phenobarbital17
Cigarette smoke17,29 Phenytoin26
Omeprazole17 Rifampicin17,31
St John´s wort32
1Bertz & Granneman 1997, 2Ozono et al. 2002, 3Wang et al. 2000, 4Härtter et al. 2001, 5Callaghan et al. 1999, 6Oda et al. 1995, 7Granfors et al. Study
I, 8Fuhr et al. 2005, 9Rettie et al. 2000, 10Wang et al. 2002, 11Backman et al. 2002, 12Niemi et al. 2003a, 13Niemi et al. 2003b, 14Becquemont et al.
1999, 15Yu et al. 2003, 16Klotz et al. 2004, 17Pelkonen et al. 1998, 18Spaldin et al. 1994, 19Bachmann et al. 2003, 20Wen et al. 2002, 21Walsky et al.
2005, 22Furuta et al. 1999, 23Zanger & Eichelbaum 2000, 24Brøsen et al. 1993a, 25Bailey et al. 2004, 26Wrighton & Thummel 2000, 27Back & Tjia
1991a, 28Parker et al. 1998, 29Miners & McKinnon 2000, 30Gerbal-Chaloin et al. 2001, 31Niemi et al. 2003c, 32Dürr et al. 2000.
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1.2.1. CYP1A subfamily
CYP1A1 and CYP1A2 are the two members of the CYP1A subfamily. CYP1A1 is
expressed mainly in extrahepatic tissue, and is of little importance in drug
metabolism (Miners & McKinnon, 2000). CYP1A2 is abundantly expressed in the
human liver, and it can also be expressed in some extrahepatic tissues, such as the
gastrointestinal tract (Ding & Kaminsky 2003). CYP1A2 metabolises, for example,
caffeine, tacrine, clozapine, ropivacaine, theophylline, lidocaine and melatonin
(Butler et al. 1989, Madden et al. 1993, Bertilsson et al. 1994, Oda et al. 1995, Tjia
et al. 1996, Wang et al. 2000, Härtter et al. 2001). Caffeine is often used as a probe
substrate for CYP1A2. For example, the caffeine/paraxanthine ratio is a suitable
index of CYP1A2 activity in vivo (Butler et al. 1989, Fuhr & Rost 1994). CYP1A2
is inhibited by, for example, fluvoxamine and ciprofloxacin, and induced by, for
example, cigarette smoking and other compounds containing polycyclic aromatic
hydrocarbons (PAH) (Table 1). CYP1A enzymes transform some procarcinogens,
such as PAH compounds and aflatoxin B1, to carcinogens (Miners & McKinnon
2000).
CYP1A2 activity shows interindividual variability which seems to be explained by
both genetic and environmental factors (Rasmussen et al. 2002, Aklillu et al. 2003).
In 378 Danish twins, heritability accounted for an estimated 73% of the variability in
CYP1A2 activity, while environmental effects seemed to account for the remainder
(Rasmussen et al. 2002). Even though there is genetic polymorphism in the CYP1A2
gene (www.imm.ki.se/CYPalleles/cyp1a2.htm), no nucleotide differences that
clearly explain the phenotypic variability in CYP1A2 gene expression or inducibility
have been identified. A single nucleotide polymorphism (SNP), -164C>A, the allele
CYP1A2*1F, has been associated with higher inducibility of CYP1A2 activity
(Chida et al. 1999, Sachse et al. 1999, Bondolfi et al. 2005), but this has not been
confirmed in all studies (Schulze et al. 2001, Nordmark et al. 2002, Shimoda et al.
2002, Kootstra-Ros et al. 2005). Aklillu et al. (2003) have suggested that the -
164C>A SNP occurs in at least four different haplotypes having different functional
impact, and thus complete haplotypes, rather than single SNPs, should be considered
when phenotype associations are investigated. Additionally, other point mutations
have been identified that lead to both lower enzyme activity and inducibility
(Nakajima et al. 1999, Aklillu et al. 2003).
1.2.2. Other CYP enzymes
CYP2B6. The expression of CYP2B6 in human liver, and its role in hepatic drug
clearance, has earlier been considered to be rather insignificant (Mimura et al. 1993,
Shimada et al. 1994). However, recent studies have suggested higher abundance of
hepatic CYP2B6 with significant interindividual variability (Gervot et al. 1999,
Hesse et al. 2000). Substrates of CYP2B6 are, for example, nevirapine, bupropion,
propofol and ketamine (Erickson et al. 1999, Hesse et al. 2000, Court et al. 2001,
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Hijazi & Boulieu 2002). The activity of CYP2B6 can be inhibited by fluvoxamine,
sertraline, paroxetine, hormone replacement therapy, clopidogrel, and ticlopidine
(Hesse et al. 2000, Palovaara et al. 2003, Turpeinen et al. 2005) and induced by, for
example, phenobarbital and cyclophosphamide (Gervot et al. 1999). The CYP2B6
gene is highly polymorphic and the CYP2B6*6 mutation may have clinical
relevance as it increases the 4-hydroxylation of cyclophosphamide (Xie et al. 2003).
The CYP2B6*4 mutation may also have clinical relevance as it increases the
clearance of bupropion (Kirchheiner et al. 2003).
CYP2C subfamily. The human CYP2C isoforms are primarily hepatic, but they
exist in the small intestine as well, and include CYP2C8, CYP2C9, CYP2C18, and
CYP2C19. CYP2C18 does not seem to be clinically important. Paclitaxel is the
prototypic substrate for CYP2C8, and trimethoprim and montelukast are its selective
inhibitors (Rettie et al. 2000, Wen et al. 2002, Walsky et al. 2005). Substrates of
CYP2C9 are, for example, S-warfarin and ibuprofen (Bertz & Granneman 1997) and
sulfaphenazole is a prototypic inhibitor (Rettie et al. 2000). For CYP2C19,
hydroxylation of S-mephenytoin is a prototypic reaction, and omeprazole can serve
as a selective inhibitor (Ko et al. 1997, Pelkonen et al. 1998). Several proton pump
inhibitors are also substrates of CYP2C19 (Klotz et al. 2004). Other substrates,
inhibitors and inducers are given in Table 1. CYP2C9 and CYP2C19 exhibit genetic
polymorphism, with clinical consequences (Goldstein 2001). For example, the
CYP2C9 and CYP2C19 genotypes are relevant to warfarin and proton pump
inhibitor doses, respectively (Daly 2003, Furuta et al. 2005).
CYP2D6. Even though the amount of CYP2D6 is rather low compared to, for
example, CYP3A4 and CYP1A2 in human liver, it metabolises approximately 30%
of all drugs (Fromm et al. 1997). Codeine, fluoxetine, fluvoxamine and tramadol are
some substrates of CYP2D6 (Table 1). CYP2D6 is inhibited by several agents, such
as its own substrates fluoxetine and paroxetine (Belpaire et al. 1998). Quinidine is a
selective inhibitor of CYP2D6 (Newton et al. 1995). CYP2D6 seems not to be
inducible, in contrast to all other CYP enzymes involved in human drug metabolism
(Zanger & Eichelbaum 2000). CYP2D6 is polymorphically expressed;
approximately 7% of the Caucasians lack functional CYP2D6 enzyme, being poor
metabolisers (PMs) (Mahgoub et al. 1977, Alvan et al. 1990). In contrast,
individuals with a duplicated or multiplicated CYP2D6 gene have very high
CYP2D6 activity and are called ultrarapid metabolisers (UMs) (Johansson et al.
1993).
CYP2E1. CYP2E1 participates in the metabolism of only a few drugs, often
forming toxic metabolites. Ethanol is both a substrate and inducer of CYP2E1
(Klotz & Ammon 1998). Furthermore, CYP2E1 also metabolises, for example,
paracetamol (acetaminophen), halothane, chlorzoxazone, and mediates activation of
many carcinogens (Klotz & Ammon 1998, Raucy & Carpenter 2000). In vitro,
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CYP2E1 is inhibited by diethyldithiocarbamate, although not specifically (Eagling
et al. 1998).
CYP3A subfamily. CYP3A4, CYP3A5 and CYP3A7 belong to the CYP3A
subfamily and seem to have similar substrate specificities (Wrighton & Thummel
2000). CYP3A7 is poorly expressed in the adult human liver, but in fetal human
liver it accounts for some 50% of all expressed CYP enzymes (Wrighton et al. 1988,
Koch et al. 2002).
  CYP3A4 is one of the most important drug-metabolising CYP enzymes in humans.
In addition to the abundant expression of CYP3A4 in the liver (approximately 30%),
it is the dominant CYP enzyme in the small intestinal mucosa (Shimada et al. 1994,
Kivistö et al. 1996, Zhang et al. 1999). It has been suggested that approximately
50% of all clinically used drugs that are metabolised are substrates of CYP3A4
(Table 1). For example, midazolam 1-hydroxylation and testosterone 6-
hydroxylation are commonly used probe reactions for CYP3A activity (Pelkonen et
al. 1998, Wrighton & Thummel 2000). Hepatic and intestinal CYP3A4 are induced
by several drugs, for example rifampicin (rifampin), carbamazepine, phenytoin, and
St John`s wort (Hypericum Perforatum) (Backman et al. 1996a, Backman et al.
1996b, Pelkonen et al. 1998, Dürr et al. 2000).
  CYP3A5 is, in contrast to CYP3A4, polymorphically expressed (Kuehl et al.
2001). CYP3A5 can be found in significant levels in approximately 10-40% of
Caucasians, 40-50% of Chinese and more than 50% of African Americans
(Wrighton et al. 1990, Tateishi et al. 1999, Chou et al. 2001, Kuehl et al. 2001).
According to recent findings, CYP3A5 often represents more than 50% of the total
hepatic CYP3A in individuals expressing CYP3A5 (Kuehl et al. 2001), and
expression of CYP3A5 is associated with reduced concentrations, faster metabolism
or reduced efficacy of several CYP3A substrates, such as statins (Kivistö et al.
2004) and tacrolimus (Hesselink et al. 2003).
1.3. CYP enzyme inhibition and induction
Environmental factors such as drugs, but also, for example, tobacco smoking,
charcoal-grilled meat, and grapefruit juice, can inhibit or induce CYP enzymes. The
inhibition or induction of drug metabolism can cause great variation in the plasma
concentrations and effects of a drug. For example, the total area under the AUC(0-
?) of the CYP3A4 substrate midazolam was approximately 400 times larger during
concurrent treatment with itraconazole than after treatment with rifampicin
(Backman et al. 1998).
Inhibition of CYP enzymes. Inhibition of CYP enzymes by xenobiotics, at certain
concentrations, is often selective for a limited number of isoforms. For example,
itraconazole is a potent and relatively selective inhibitor of CYP3A4 (Back & Tjia
1991a). The fluoroquinolone antibiotic ciprofloxacin inhibits mainly CYP1A2
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(Bertz & Granneman 1997) and paroxetine inhibits mainly CYP2D6 (Jeppesen et al.
1996).
  Ki is an inhibition constant related to the affinity of a compound to an enzyme, and
is important in predicting in vivo drug-drug interactions resulting from metabolic
inhibition. Ki can be estimated in vitro either graphically by plotting methods or by
nonlinear regression analysis. The mechanisms of CYP inhibition include reversible
inhibition, quasi-irreversible and irreversible inhibition.
Reversible inhibition can be further divided, based on enzyme kinetics, into
competitive, noncompetitive, and uncompetitive. In competitive inhibition, the
inhibitor competes with the substrate for the active site of the free enzyme (for
example the CYP3A4 inhibitor itraconazole, von Moltke et al. 1996). In
noncompetitive inhibition, the inhibitor binds to a different binding site of the
enzyme and has no effect on the binding of the substrate (for example the inhibition
of the CYP3A-catalysed conversion of dextrometorphan to 3-methoxymorphinan by
omeprazole, Ko et al. 1997). In uncompetitive inhibition, the inhibitor binds only to
an enzyme-substrate complex, not to the free enzyme (for example the CYP2E1
inhibitor cotinine, Van Vleet et al. 2001).
In quasi-irreversible inhibition, an inhibitor is metabolically activated by the CYP
enzyme, and then this inhibitory metabolite forms a stable metabolic intermediate
(MI) complex with the prosthetic heme of CYP, rendering the enzyme functionally
inactive. MI complexation can be reversed in vitro but not in vivo, hence the name
quasi-irreversible (Lin & Lu 1998). Erythromycin is an example of a quasi-
irreversible inhibitor of CYP3A (Thummel & Wilkinson 1998).
In irreversible inhibition, a drug is oxidized by the CYP to a reactive intermediate,
which covalently binds to the enzyme causing irreversible inactivation. This kind of
inhibition is also called mechanism-based or suicide inhibition (Lin & Lu 1998,
Thummel & Wilkinson 1998). Mechanism-based inhibitors of CYP enzymes in vitro
are, for example, furafylline (CYP1A2), gestodene (CYP3A4) and ethinylestradiol
(CYP3A4) (Guengerich 1990a, Kunze & Trager 1993, Lin & Lu 1998).
Induction of CYP enzymes. Induction of CYP1A enzymes is usually mediated by
formation of a dimer of the cytosolic aryl hydrocarbon receptor (AhR) and the AhR
nuclear translocator protein (Arnt). This dimer binds to the deoxyribonucleic acid
(DNA) at Ah-responsive element sequences, and thus elevates the transcription
levels of the CYP1A genes (Miners & McKinnon 2000). The large interindividual
variation in CYP1A inducibility is probably linked to genetic polymorphism in
AhR; studies suggest an increased risk for malignancies in individuals who have the
high-affinity AhR phenotype (Miners & McKinnon 2000). Other enzymes induced
by this mechanism include some phase II enzymes such as GSTs and UGTs.
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Induction of CYP3A4 is mediated by nuclear receptors: pregnane X receptor (PXR),
constitutive androstane receptor (CAR), and glucocorticoid receptor (Gibson &
Skett 2001). In order to activate the CYP3A4 gene, PXR and CAR first have to bind
to an inducer, and thereafter form heterodimers with the retinoid X receptor (RXR)
which binds to specific gene regulation elements (Gibson & Skett 2001).
There are also other mechanisms of CYP enzyme induction, for example ethanol
induces CYP2E1 primarily by stabilizing the enzyme (Fuhr 2000).
1.4. Drug transporters
Transport processes are increasingly acknowledged as important determinants of
absorption, distribution and excretion of drugs through cell membranes. It is often
necessary to consider both metabolism (by CYP enzymes) and transport
mechanisms (by drug transporters) together when predicting in vivo
pharmacokinetics (Kusuhara & Sugiyama 2002). It is not known whether tizanidine
is a substrate for any drug transporter.
The main efflux transporter is P-glycoprotein (P-gp). P-gp is involved in the
excretion of substances into the gut, bile, and urine, and is considered to play an
important role in the blood-brain, blood-testes, and blood-placenta barriers (Lo &
Burckart 1999). P-gp has overlapping substrate specificity with CYP3A4 (for
example diltiazem, nifedipine, HIV protease inhibitors) (Lin & Yamasaki 2003).
However, important exceptions exist: digoxin is eliminated almost entirely by
excretion, but is a prototypical P-glycoprotein substrate susceptible to clinically
relevant drug interactions with P-gp inhibitors (for example itraconazole, verapamil,
cyclosporin, quinidine) (Partanen et al. 1996, Fromm et al. 1999, Silverman 2000).
Midazolam is a substrate of CYP3A4 but not of P-gp (Kim et al. 1999).
Uptake transporters are, for example, sodium (Na+)-dependent taurocholate co-
transporting polypeptide (NTCP) and the organic anion-transporting polypeptides
superfamily (OATP). Multidrug resistance protein 2 (MRP2, also known as
cMOAT) and MRP3 are further examples of efflux transporters. MRP1 is
minimally, if at all, expressed in normal human liver. MRP2, MRP3, NTCP and
certain OATPs are important, for example, in bile salt transport, regulating the
enterohepatic circulation of the bile salt pool, and in uptake and efflux of drugs into
and out from hepatocytes (Trauner & Boyer 2003).
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2. Tizanidine
Tizanidine [5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiodiazole hydro-
chloride] is a centrally-acting skeletal muscle relaxant that has been in clinical use
for over 20 years (brand names, Sirdalud® and Zanaflex®). In addition to its use in
chronic spasticity conditions such as multiple sclerosis (MS), tizanidine is
commonly used, for example, in migraine, tension-type headache and
musculoskeletal pain (Wagstaff & Bryson 1997, Lake & Saper 2002, Freitag 2003).
The chemical structure (Figure 1) of tizanidine (molecular weight 253.72) is related
to other ?2-adrenoceptor agonists such as the antihypertensive drugs clonidine and
moxonidine (Koch et al. 1989).
2.1. Pharmacodynamics
Tizanidine is an ?2-adrenergic agonist and reduces spasticity presumably by
increasing presynaptic inhibition of motor neurons. By stimulating presynaptic ?2-
receptors tizanidine inhibits the release of catecholamines (norepinephrine, i.e.
noradrenaline), thereby inhibiting the stimulation of N-methyl-D-aspartate (NMDA)
receptors. The transmission of polysynaptic signals is hence inhibited and muscle
tone is decreased (Davies 1982, Coward 1994).
Besides its spasticity reducing effect, the pharmacodynamic effects of tizanidine are
in most cases undesirable but still common in many patients, and closely resemble
those of clonidine. These effects are probably mediated by ?2-adrenergic agonism;
the inhibition of norepinephrine release leads to decreased activity of the
sympathetic nervous system and hence to the hypotension and bradycardia
associated with tizanidine use. Other effects due to ?2-adrenergic agonism in the
central nervous system are, for example, sedation and tiredness, muscle weakness,
dizziness, and dry mouth (Miettinen et al. 1996).
Use in neurological spasticity. Spasticity is a common problem among
neurological rehabilitation patients, for example patients with MS or traumatic
spinal cord injury (SCI). Tizanidine reduces spasticity caused by spinal cord and
brain injuries. The reduction of muscle tone correlates with tizanidine plasma
concentration, but the plasma concentrations vary interindividually at a given dose
(Emre et al. 1994, Roberts et al. 1994, Nance et al. 1997). Tizanidine has a similar
anti-spastic efficacy as diazepam and baclofen (Lataste et al. 1994, Wallace 1994)
and can be used in combination with other antispastic agents with different
mechanisms of action, such as baclofen.
Central nervous system effects. In a multiple dose study, nearly half of the 111
patients receiving 2 to 36 mg of tizanidine reported sedation as an adverse event,
compared to only 3 of the 109 patients receiving placebo (Smith et al. 1994).
Furthermore, dry mouth and dizziness were reported in almost 60% and 20%,
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respectively, of patients receiving tizanidine, compared to 15% and 5% of patients
taking placebo (Smith et al. 1994). Similar results have been noted in other studies
(the United Kingdom Tizanidine Trial Group 1994, Wallace 1994). Sedation,
dizziness and dry mouth seem to be the most common side effects related to
tizanidine. Hallucinations are less common, but have occurred in 3 of 525 patients
with MS or SCI using tizanidine (Wallace 1994).
Cardiovascular effects. As tizanidine is an ?2-adrenergic agonist, like clonidine, it
can lower blood pressure. In two clinical studies with healthy volunteers,
significantly greater decreases in systolic blood pressure (of 9% to 10% from
baseline) and diastolic blood pressure (of 7% to 15% from baseline) than in placebo
recipients were noted (Taittonen et al. 1995, Miettinen et al. 1996). Similar results
have been found in patients with spinal injuries (Mathias et al. 1989). The reduction
in blood pressure occurs within 1 hour after dosing, peaking 2 to 3 hours after
dosing of a conventional formulation, and it has been associated with bradycardia,
orthostatic hypotension, dizziness and rarely syncope. Animal experiments have
indicated that tizanidine also binds to imidazoline receptors, in addition to ?2-
adrenoceptors (Honda et al. 2002). A link with the hypotensive response to
tizanidine has been postulated (Muramatsu & Kigoshi 1992).
Other effects. Tizanidine is suggested to have antinociceptive properties, mediated
via ?2-adrenoceptors rather than opioid receptors (Wagstaff & Bryson 1997), and
might therefore be an effective, adjunctive prophylactic agent for the treatment of
several types of chronic daily headache (Lake & Saper 2002). However, this has not
been confirmed by all studies (Murros et al. 2000).
Tizanidine may cause adverse hepatic effects, but these are uncommon. Two of
525 patients with MS or SCI using tizanidine had elevations in liver function
laboratory tests. These elevations resolved rapidly upon dose reduction or drug
withdrawal (Wallace 1994).
Tizanidine might have gastrointestinal effects, for example reduction of gastric acid
secretion, probably by stimulating gastric and central ?2-adrenoceptors (Maeda-
Hagiwara 1985, Emre 1998, Jain et al. 2002). Tizanidine is thus suggested to reduce
the frequency of adverse gastrointestinal effects induced by non-steroidal anti-
inflammatory drugs (NSAIDs) (Emre 1998).
2.2. Pharmacokinetics
The pharmacokinetic properties of tizanidine after single oral doses (2, 4 or 8 mg)
have been investigated in healthy volunteers and in patients with MS or SCI
(Heazlewood et al. 1983, Koch et al. 1989, Mathias et al. 1989, Emre et al. 1994). In
the study by Tse et al. (1987), the pharmacokinetics of tizanidine 4 mg given 3 times
a day for 4 days was investigated in healthy volunteers.
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Absorption. Tizanidine is rapidly absorbed in healthy volunteers and patients with
MS or SCI, reaching peak plasma concentrations (Cmax) in approximately 1 hour
(0.75 to 2 hours) (time to reach Cmax; tmax) (Heazlewood et al. 1983, Tse et al. 1987,
Koch et al. 1989, Mathias et al. 1989, Emre et al. 1994). The ingestion of food has
no significant effect on the pharmacokinetics of tizanidine (Wagstaff & Bryson
1997). The bioavailability of tizanidine has been estimated to average 20% to 40%,
as a result of extensive first-pass metabolism (Tse et al. 1987, Zanaflex product
information). Yet the exact value is not known since tizanidine was not given
intravenously (Tse et al. 1987).
Distribution. Tizanidine is widely distributed throughout the body; the mean steady
state volume of distribution is 2.4 l/kg following intravenous administration in
healthy adult volunteers (Zanaflex product information). The pharmacokinetics of
tizanidine are linear in the 1 to 20 mg dose range (Tse et al. 1987). Tizanidine seems
to have low propensity for binding to plasma proteins and blood cells
(approximately 30%), independent of concentration over the therapeutic range
(Koch et al. 1989).
Metabolism. Tizanidine is extensively metabolised in the liver during the first-pass
(Tse et al. 1987, Koch et al. 1989). Tizanidine is biotransformed to several
metabolites (for example M-3, M-4, M-5, M-9, M-10) (Figure 1), of which M-3 and
M-4 (formed from M-3) are the main metabolites in plasma (Koch et al. 1989). The
metabolites appear to have no pharmacological activity (Koch et al. 1989). The
contribution of CYP enzymes to tizanidine metabolism was unknown until the
present thesis work.
Elimination. Following oral administration, the t1/2 of tizanidine is approximately
2.5 hours (Heazlewood et al. 1983, Tse et al. 1987, Koch et al. 1989, Mathias et al.
1989, Emre et al. 1994). Tizanidine is mainly excreted as metabolites in urine
(70%), and only partly via the faeces (30%) (Tse et al. 1987, Koch et al. 1989).
Approximately 3% of the dose is excreted in urine as unchanged tizanidine (Koch et
al. 1989). According to the manufacturer, younger subjects clear tizanidine four
times faster than elderly subjects. Sex does not seem to have no effect on tizanidine
pharmacokinetics (Zanaflex product information).
2.3. Clinical use
Tizanidine is available as tablets containing 2 mg and 4 mg tizanidine
(hydrochloride) and a depot-capsule containing 6 mg. The optimal drug response is
usually achieved at a dose of 12 to 24 mg per day, divided into three or four doses.
The maximal daily dose is 36 mg (Wagstaff & Bryson 1997).
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2.4. Drug interactions
Before this thesis work, very little was known about pharmacokinetic drug
interactions with tizanidine. One study had shown that it is unlikely that
coadministration of tizanidine and baclofen would result in a pharmacokinetic
interaction (Shellenberger et al. 1999). The product information for Zanaflex states
that OCs decrease the clearance of tizanidine by 50%, but this information is based
on unpublished data. Due to the cardiovascular effects of tizanidine, concomitant use
with antihypertensive drugs might result in hypotension and bradycardia. The
sedative effect of tizanidine may be additive when tizanidine is taken in conjunction
with substances that act as central nervous system depressants.
Figure 1. Structures of tizanidine and its metabolites and the proposed metabolic pathways
involved. Figures in parenthesis indicate theoretically possible intermediates. Adapted from Koch
et al. 1989.
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3. Caffeine
Caffeine (1,3,7-trimethylxanthine) is a central nervous system stimulant which
appears in many dietary sources (mainly coffee, tea and soft drinks). Caffeine
increases alertness by inhibiting adenosine receptors in the brain (Carrillo & Benitez
2000). In addition, the diuretic, metabolic and some cardiac effects seem to be
explained by this mechanism.
Caffeine is rapidly and completely absorbed after oral administration, with the Cmax
occurring in approximately 1 hour (Carrillo & Benitez 2000). The volume of
distribution of caffeine is approximately 0.6 l/kg. There is no evidence of
presystemic metabolism, but elimination is almost entirely dependent on hepatic
metabolism in adults (Dollery 1999). Caffeine is metabolised mainly into
paraxanthine (1,7-dimethylxanthine, 72% to 84% of an oral caffeine dose) by
CYP1A2, other metabolic pathways being less significant (Figure 2). The
caffeine/paraxanthine ratio in plasma has been used for assessing CYP1A2 activity
in humans (Fuhr et al. 1996, Spigset et al. 1999). The other demethylated caffeine
metabolites, theobromine (3,7-dimethylxanthine, 11% to 20% of an oral caffeine
dose) and theophylline (1,3-dimethylxanthine, 5% to 8% of an oral caffeine dose),
are produced primarily via CYP1A2 and a small proportion via CYP2E1. These
main metabolites are further demethylated and oxidated (Dollery 1999, Carrillo &
Benitez 2000). The t1/2 of caffeine and paraxanthine are approximately 3 to 4 hours,
respectively (Lelo et al. 1986).
Caffeine may have some interaction potential as a CYP1A2 inhibitor in humans
(Pelkonen et al. 1998). In fact, caffeine has reduced the clearance of theophylline by
23% (Sato et al. 1993), and increased the Cmax and AUC of melatonin by 142% and
120%, respectively (Härtter et al. 2003). However, coffee drinking had no clinically
relevant effect on serum clozapine concentrations (Raaska et al. 2004).
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Figure 2. Major metabolic pathways of caffeine with the primary enzymes shown at each
important step. The thickness of each arrow indicates the relative importance of each pathway. 1-U
= 1-methyluric acid; 1-X = 1-methylxanthine; 17-U = 1,7-dimethyluric acid; AFMU = 5-
acetylamino-6-formylamino-3-methyluracil; NAT2 = N-acetyltransferase type 2; XO = xanthine
oxidase. Adapted from Carrillo & Benitez, 2000.
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4. CYP1A2-inhibitors used in this study
4.1. Fluvoxamine
Fluvoxamine (Figure 3) is a selective serotonin (5-hydroxytryptamine) reuptake
inhibitor (SSRI), used in the treatment of depression (Perucca et al. 1994). Its other
therapeutic indications include obsessive-compulsive disorder, anxiety, and eating
disorders (Perucca et al. 1994, Figgitt & McClellan 2000). The daily doses in adults
range from 50 to 300 mg (Perucca et al. 1994). Fluvoxamine has little or no effect
on other monoamine (for example norepinephrine, dopamine) reuptake mechanisms
(Figgitt & McClellan 2000).
Figure 3. Chemical structure of fluvoxamine.
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Pharmacokinetics. Fluvoxamine is almost completely absorbed in the
gastrointestinal tract (Figgitt & McClellan 2000). After repeated administration of
100 mg/day, the Cmax of fluvoxamine of approximately 70 µg/l is reached within 2 to
8 hours after administration. Approximately 77% of fluvoxamine is bound to plasma
proteins (Figgitt & McClellan 2000). Fluvoxamine undergoes extensive oxidative
metabolism, primarily by the hepatic CYP enzymes CYP2D6 and CYP1A2 (Spigset
et al. 1995, Carrillo et al. 1996), with only approximately 3% of an oral dose being
excreted unchanged in the urine. The oral bioavailability and volume of distribution
of fluvoxamine are unknown because it has not been given intravenously to humans.
The t1/2 of fluvoxamine varies between 7 to 60 hours and steady state requires about
10 days in individuals with the longest t1/2 (Dollery 1999).
Adverse effects. Fluvoxamine is generally well tolerated but nausea may occur in
patients. Somnolence, asthenia, headache, dry mouth and insomnia have also been
reported, but these are less common (Figgitt & McClellan 2000).
Interactions. Fluvoxamine is a potent inhibitor of CYP1A2 and CYP2C19, and a
moderate inhibitor of CYP3A4, CYP2D6 and CYP2C9 (Hemeryck & Belpaire
2002), and may therefore interact with substrates of these enzymes. In vitro,
fluvoxamine was a very potent inhibitor of the formation of caffeine metabolites,
displaying Ki values of 0.08 µM to 0.28 µM (Rasmussen et al. 1998). In humans,
fluvoxamine considerably increases the plasma concentrations of CYP1A2 substrate
drugs, such as tacrine, clozapine, ropivacaine, theophylline and caffeine
Review of the literature
29
(Becquemont et al. 1997, Chang et al. 1999, Jokinen et al. 2000, Yao et al. 2001,
Christensen et al. 2002).
4.2. Ciprofloxacin
Ciprofloxacin (Figure 4) is a broad-spectrum fluoroquinolone antimicrobial agent
showing activity against Gram-negative bacteria (Davis et al. 1996).
Fluoroquinolones target bacterial topoisomerases, arresting DNA replication.
Effective therapeutic regimens for different infections vary from single doses of 250
mg to 750 mg, to administration three times per day for up to several months
(Dollery 1999).
Figure 4. Chemical structure of ciprofloxacin.
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Pharmacokinetics. The oral bioavailability of ciprofloxacin is 50% to 85% and its
Cmax, from oral administration of 500 mg, is 1.5 mg/l. Its tmax ranges from 60 to 75
min (Dollery 1999). The volume of distribution is between 1.7 and 2.5 l/kg, and
approximately 20% to 40% of ciprofloxacin in plasma is bound to plasma protein.
The ciprofloxacin concentration in cerebrospinal fluid is approximately 50% of
serum concentration, penetration into other tissues is good in most cases.
Ciprofloxacin is eliminated mainly in the unchanged form, with approximately 30%
of the dose being metabolised. Its t1/2 is 3 to 4 hours; in comparison with
fluvoxamine, ciprofloxacin has a shorter half-life, better water-solubility, and
smaller extent of metabolism (Dollery 1999).
Adverse effects. Nausea and diarrhea are the most common adverse effects caused
by ciprofloxacin. Skin reactions may also occur. CNS symptoms, such as
restlessness, dizziness, headache and tremor are seen in approximately 3% of
patients (Bertino 2000). Fluoroquinolones are associated with tendon disorders,
which seem to especially affect corticosteroid-using patients over 60 years of age
(Stahlmann & Lode 2003).
Interactions. Ciprofloxacin is a moderate inhibitor of CYP1A2-mediated drug
metabolism (Fuhr et al. 1992, Bertz & Granneman 1997). In vitro, ciprofloxacin has
inhibited caffeine metabolism with a Ki of 0.2 mM (Fuhr et al. 1990). In humans,
ciprofloxacin has been found to impair the elimination of theophylline, caffeine,
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clozapine and ropivacaine (Wijnands et al. 1986, Harder et al. 1988, Batty et al.
1995, Raaska & Neuvonen 2000, Jokinen et al. 2003). In general, the extent of the
interactions caused by ciprofloxacin have been considerably smaller than those
caused by fluvoxamine; yet there seem to be no direct comparisons of their effects
on orally administered CYP1A2 substrates, particularly on those with extensive
first-pass metabolism.
  Ferrous sulphate has been shown to reduce the AUC and Cmax of ciprofloxacin by
more than 50% (Lehto et al. 1994). Oral iron and zinc ions and antacids containing
magnesium, aluminium, calcium and sucralfate may reduce the oral bioavailability
of ciprofloxacin to 15% by inhibiting its absorption (Brouwers 1992). Concomitant
ingestion of yoghurt or milk also reduces the bioavailability of ciprofloxacin
(Neuvonen et al. 1991).
4.3. Oral contraceptives (OCs)
Contraception by means of ingesting steroid-containing pills was introduced in the
1960s, and their use has increased extensively since then. Today, OCs are the most
widely prescribed drugs all over the world and the variety of different OC
preparations has expanded. Traditionally, OC preparations are combinations of
estrogenic and progestagenic steroids. Ethinylestradiol is the major estrogenic
steroid used in combined OCs, but the selection of progesterones (for example
gestodene, levonorgestrel and desogestrel) combined with ethinylestradiol is vast.
OCs have been found to reduce the clearance of the CYP1A2 substrates
theophylline, caffeine and antipyrine by 30% to 55%, but the Cmax of caffeine and
theophylline have not been affected (Tornatore et al. 1982, Roberts et al. 1983,
Rietveld et al. 1984, Abernethy & Todd 1985, Pazzucconi 1991, Balogh et al. 1995,
Rasmussen et al. 2002). Additionally, the metabolism of several substrates of
CYP3A4, for example benzodiazepines, alprazolam and methylprednisolone (Stoehr
et al. 1984, Kroboth et al. 1985, Scavone et al. 1988, Slayter et al. 1996, Belle et al.
2002), and of CYP2C19, for example mephenytoin and omeprazole (Laine et al.
2000, Hägg et al. 2001) have been inhibited when concomitantly used with OCs.
4.3.1. Ethinylestradiol
Figure 5. Chemical structure of ethinylestradiol.
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(17?-) ethinylestradiol (Figure 5) is a potent estrogenic steroid, rapidly absorbed
from the gastrointestinal tract. Ethinylestradiol is subject to significant first-pass
metabolism in the intestinal wall and thus its oral bioavailability is less than 50%
(Orme et al. 1983). After a single dose of 30 µg ethinylestradiol and 75 µg
gestodene, the Cmax (approximately 75 pg/ml) of ethinylestradiol is reached in 1 to 2
hours (Jung-Hoffmann & Kuhl 1990). However, there are large variations in
ethinylestradiol pharmacokinetics between subjects. The plasma concentration of
ethinylestradiol reaches a steady state (approximately 100 pg/ml) in approximately
10 days (Jung-Hoffmann & Kuhl 1990). The major metabolic pathway of
ethinylestradiol is 2-hydroxylation, which is catalysed by CYP3A4, CYP2C9 and
CYP1A2 in vitro (Wang et al. 2004). Its t1/2 varies from 6 to 24 hours (Orme et al.
1983, Jung-Hoffman & Kuhl 1990). Ethinylestradiol has mechanism-based,
inhibitory effects on CYP3A4, CYP2B6, CYP2C9, and CYP2C19 activities in vitro
(Guengerich 1990b, Kent et al. 2002, Lin et al. 2002, Laine et al. 2003). The effect
of ethinylestradiol on CYP1A2 activity has been only poorly investigated in vitro.
4.3.2. Gestodene
Figure 6. Chemical structure of gestodene.
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Gestodene (Figure 6) is rapidly absorbed from the gastrointestinal tract with a high
oral bioavailability. Its Cmax (approximately 5 ng/ml after single dose administration
of 75 µg gestodene and 30 µg ethinylestradiol) is reached 30 min to 4 hours after
ingestion (Täuber et al. 1990, Wilde & Balfour 1995). However, there are large
interindividual variations in gestodene pharmacokinetics. Gestodene is extensively
metabolised in the liver, producing several metabolites (Täuber et al. 1990, Ward &
Back 1993, Wilde & Balfour 1995). The t1/2 of gestodene varies between 12 to 24
hours (Wilde & Balfour 1995). Gestodene reaches a steady state within 10 days, the
steady state concentrations being up to 4 or 5 times higher than after single dose
administration (Täuber et al. 1990, Kaplan 1995). Ethinylestradiol induces the
formation of sex hormone-binding globulin (SHBG), to which gestodene binds, and
therefore plasma gestodene concentrations can continue to increase for the whole
cycle (Jung-Hoffmann & Kuhl 1990, Dollery 1999). However, as the fraction of free
protein-unbound gestodene is reduced in concert with an increased level of SHBG-
bound gestodene, the concentration of free gestodene does not necessarily increase
(Hammond et al. 1994). Gestodene is a potent inhibitor of CYP3A4 (Guengerich
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1990a, Laine et al. 2003), and CYP2C19 (Back et al. 1991b, Laine et al. 2003), but
it seems to have no significant effect on CYP1A2 in vitro (Guengerich 1990a).
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AIMS OF THE STUDY
Tizanidine has extensive presystemic metabolism, and metabolism is crucial also for
its systemic elimination. Thus, tizanidine may be susceptible to pharmacokinetic
drug interactions, but, previously, these have been only poorly studied. Adverse
effects of tizanidine, for example drowsiness, dizziness and decrease in blood
pressure, are not uncommon. Before this study, no controlled studies were available
concerning the CYP enzymes involved in the metabolism of tizanidine, or the
effects of CYP enzyme inhibition on tizanidine pharmacokinetics.
The specific aims of the studies were to:
1) investigate in vitro whether tizanidine is metabolised by CYP enzymes and
identify the CYP enzymes mainly responsible for its elimination, and evaluate
potential in vivo drug interactions (Study I),
2) investigate a possible interaction of fluvoxamine with tizanidine in humans
(Study II),
3) investigate a possible interaction of ciprofloxacin with tizanidine in humans
(Study III),
4) investigate a possible interaction of OCs, containing ethinylestradiol and
gestodene, with tizanidine in humans (Study IV), and
5) compare caffeine and tizanidine as probe substrates of CYP1A2 in humans
(Study II to IV).
Materials and methods
34
MATERIALS AND METHODS
1. In vitro study (Study I)
1.1. Metabolism of tizanidine in human liver microsomes
The ability of human liver microsomes (HLM) to metabolise tizanidine was
determined by measuring the concentration of tizanidine remaining after its
incubation in the presence of pooled HLM. The microsomal cellular fraction is the
supernatant that is separated by centrifugation at 100,000 g to 250,000 g for 60 to
120 min and consists of “pinched-off” closed vesicles of fragments of endoplasmic
reticular membrane (Lake 1987). Stocks of pooled HLM known to contain
representative levels of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9,
CYP2C19, CYP2D6 and CYP3A4, were purchased from Gentest Corp (Woburn,
MA, USA). Gentest Corp had received the liver samples from several organ
procurement organizations, which collect tissues in accordance with pertinent
regulations and obtain permission from the families of the donors prior to organ
collection. The procedures of these organizations have all been reviewed and
approved by their respective institutional Human Subjects Committees. Three
different pooled batches were used in this in vitro study, all prepared by Gentest
Corp from 20 human liver microsomal samples. The original protein concentration
was 20 mg/ml in each of the batches.
All incubations were conducted in a shaking water bath at 37°C in duplicate (the
duplicate data were within 7% of the mean) in 0.1 M sodium phosphate buffer (pH
7.4), containing 5.0 mM magnesium chloride (MgCl2). The initial concentration of
tizanidine used in the experiments was 80 nM (20.3 ng/ml), which is roughly at the
same level as the therapeutically relevant plasma Cmax in humans (Mathias et al.
1989, Lee et al. 2002). Tizanidine 80 nM (stock solution dissolved in methanol and
subsequently diluted with water), in some cases organic solvent with or without
inhibitor, buffer and b-NADPH (reduced form of nicotinamide adenine dinucleotide
phosphate) (1.0 mM) were premixed, and incubations were commenced by addition
of microsomes. The incubation mixture contained 1 mg/ml microsomal protein and
the total incubation volume was 1.0 ml to 2.5 ml. When substrate depletion as a
function of incubation time was measured, aliquots (0.4 ml) were removed for the
determination of tizanidine concentration at 0, 15, 30, 45, 60 and 75 min,
immediately added to 100 µl sodium hydroxide (NaOH) (0.4 M), and cooled on ice.
No nonspecific microsomal binding (1 mg/ml protein) of tizanidine was detected
using equilibrium dialysis at 37ºC for 18 hours (data not shown).
1.2. Effect of CYP inhibitors
The incubation mixture contained 1 mg/ml microsomal protein in the presence or
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absence of one of the putative inhibitors. The effects of 10 CYP inhibitors on the
metabolism of tizanidine were studied. At first screening, furafylline (20 µM) was
used as an inhibitor of CYP1A2, trimethoprim (100 µM) of CYP2C8,
sulfaphenazole (10 µM) of CYP2C9, omeprazole (10 µM) of CYP2C19, quinidine
(10 µM) of CYP2D6, diethyldithiocarbamate (100 µM) of CYP2E1, and
ketoconazole (1 µM) and troleandomycin (100 µM) of CYP3A4. As 20 µM
furafylline was found to potently inhibit tizanidine metabolism, the effects of the
CYP1A2 inhibitors furafylline (5 µM), fluvoxamine (0.1, 1.0 and 10 µM) and
ciprofloxacin (200 µM) on tizanidine elimination were studied. The final
concentrations of each inhibitor were chosen according to previous publications
(Fuhr et al. 1992, Brøsen et al. 1993b, Newton et al. 1995, Ko et al. 1997, Eagling et
al. 1998, Wen et al. 2002). The stock solutions of the inhibitors were prepared in
water and methanol. Ciprofloxacin was dissolved in water and NaOH (final
concentration 0.25%, which did not affect the activity of the microsomes).
Furafylline, troleandomycin and diethyldithiocarbamate were preincubated with the
incubation medium at 37°C for 15 min, whereafter tizanidine (final concentration 80
nM) was added. Matched control samples contained an equal volume of methanol or
NaOH. The methanol concentration in the final incubation mixtures did not exceed
0.5%. The total incubation volume was 1.0 ml and aliquots (0.4 ml) were removed at
0 and 45 min. Otherwise, the experiments were carried out as above.
1.3. Recombinant human CYP isoforms
Human recombinant CYP isoforms (SupersomesTM, Gentest Corp) from
baculovirus-infected insect cells expressing cDNA encoding human CYP1A2,
CYP2C19, CYP2E1, CYP3A4 and CYP3A5 as well as insect cell control
supersomes lacking CYP content, were examined for their abilities to catalyse
tizanidine biotransformation during incubation for 45 min. The original protein
contents were 8 mg/ml for CYP1A2 (CYP content 1000 pmol/ml), 2.4 mg/ml for
CYP2C19 (CYP content 1000 pmol/ml), 5.2 mg/ml for CYP2E1 (CYP content 2000
pmol/ml, also containing cytochrome b5; 420 pmol/mg protein), 2.3 mg/ml for
CYP3A4 (CYP content 2000 pmol/ml), and 4.5 mg/ml for CYP3A5 (CYP content
2000 pmol/ml). The microsomes and supersomes were frozen and kept at -80°C
until used. Incubations were performed using the same conditions as described
above, except that all incubation mixtures contained 30 pmol CYP/ml (for CYP1A2,
this corresponded to the activity of CYP1A2 in the pooled HLM used in the
chemical inhibition studies). The control samples contained the same protein content
as the recombinant CYP1A2 isoform.
1.4. HPLC analysis
After addition of the internal standard (clonidine 15 ng) to the incubation aliquots,
the samples were extracted twice with 2.0 ml of ethyl-acetate for 10 min (Lee et al.
2002). After centrifugation, the supernatant was evaporated under nitrogen. The
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residue was reconstituted with 100 µl of the high-performance liquid
chromatography (HPLC) mobile phase. The concentration of unchanged tizanidine
was determined by HPLC with UV (ultra violet) detection (320 nm for tizanidine
and 228 nm for clonidine). A Hewlett Packard (HP) 1100 System and Waters Xterra
RP18 reversed-phase column, 3.9 x 100 mm were used. The mobile phase was
acetonitrile:ammonium acetate (10 mM, pH 9.5) 12:88 (v/v) and the flow rate 0.75
ml/min at 35°C. The limit of quantification (peak to noise-ratio 3:1) was 10 nM, and
the coefficient of variation was 2.4% at 20 nM and 1.3% at 80 nM (n = 4).
1.5. Data analysis
Pseudo-first order rate constants were determined from measuring depletion of
tizanidine as a function of incubation time using nonlinear regression analysis; C=C0
· e(-k·t)), where C = concentration of tizanidine at time t, C0 = initial concentration of
tizanidine, k = pseudo-first order rate constant, e = 2.71828, and t = incubation time
(Naritomi et al. 2001). The t1/2 was calculated by the equation t1/2 = ln2/k.
Assuming that the concentration of tizanidine (80 nM) is much smaller than the Km
(substrate concentration at which the reaction velocity is 50% of maximum) for the
CYP-mediated metabolism of tizanidine (Km >> C0),, the intrinsic clearance (Clint, in
vitro) can be expressed by: Clint, in vitro = k/PMS, where PMS is the microsomal protein
concentration (Naritomi et al. 2001). These Clint, in vitro values were expressed per
kilogram body weight by using the standard scaling factors 48.8 mg microsomal
protein per gram liver and 25.7 gram liver per kilogram body weight (Davies &
Morris 1993, Iwatsubo et al. 1997).
The estimated hepatic clearance in vivo (Clh) values were calculated using the well
stirred model (Wilkinson 1987):
Clh = Q · fu · Clint, in vitro /(Q + fu Clint, in vitro)
and the parallel-tube model:
Clh = Q (1 – e -fu · Clint, in vitro/Q)
where Q is the hepatic blood flow (20 ml/min/kg) (Lin & Lu 1997) and fu is the
unbound fraction (0.7) (Koch et al. 1989) of tizanidine in plasma. The values
obtained were compared to the in vivo clearance of tizanidine, calculated by: Cl =
V/t1/2 · ln2, where V is the volume of distribution after intravenous administration
(2.4 l/kg) and t1/2 is the in vivo half-life (2.5 hours) for tizanidine (Zanaflex product
information).
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2. In vivo studies (Studies II to IV)
2.1. Subjects
A total of 49 (19 males in Studies II and III, and 30 females in Study IV) healthy
volunteers participated in the studies (Table 2). One male subject participated both
in Study II and III. Male subjects were chosen in Studies II and III to avoid possible
effects of menstrual cycle phases and sex on tizanidine pharmacokinetics
(Rasmussen et al. 2002, Faber et al. 2005). The volunteers were ascertained to be
healthy by medical history, physical examination, and routine laboratory tests before
entering the study. None of the subjects was using continous medication, except that
15 women in Study IV were taking OCs. For safety reasons, subjects with systolic
blood pressures lower than 110 mmHg were excluded from the study. None of the
subjects were frequent smokers. Use of other drugs and grapefruit juice was
prohibited 2 weeks prior to each study day. Use of alcohol and drinks containing
caffeine (for example cola, coffee and tea) were not allowed on the study day or the
previous day. Participation in any other trial and blood donation within 1 month
before and after the study were also prohibited.
Table 2. Characteristics of the subjects.
Study No. Subjects Age (years) Weight (kg) Height (cm) Body Mass Index
(kg/m2)
II 10 male 24 ± 3 75 ± 5 182 ± 4 23 ± 2
III 10 male 24 ± 2 80 ± 11 183 ± 3 24 ± 3
IV a) 15 female 22 ± 2 62 ± 10 168 ± 6 22 ± 3
IV b) 15 female 22 ± 2 57 ± 6 165 ± 6 21 ± 2
Age, weight, height and body mass index data are mean ± SD (standard deviation).
a) Controls, b) users of oral contraceptives containing ethinylestradiol and gestodene.
2.2. Study designs
The studies were carried out in the Department of Clinical Pharmacology,
University of Helsinki. Studies II and III were placebo-controlled, double-blinded,
randomized cross-over studies, to assess the effect of fluvoxamine and ciprofloxacin
on the pharmacokinetics and pharmacodynamics of tizanidine. Study IV was an
open, parallel group study to assess the effect of an OC containing ethinylestradiol
and gestodene on the pharmacokinetics and pharmacodynamics of tizanidine. The
OC users had taken their OC preparation for at least 1 complete cycle before the
study cycle, and they had used OCs daily for 6 to 21 days immediately before the
study day. The controls were in corresponding phases of their menstrual cycles.
Details of the studies are shown in Table 3.
The Pharmacy of the Helsinki University Central Hospital supplied each drug used,
except for the OCs. The pharmacy packaged and labelled the pretreatment
Materials and methods
38
medications and matched placebos according to a randomisation list made by the
pharmacy for each subject in Studies II and III. Drug doses were chosen to reflect
current use.
Tizanidine was administered orally with 150 ml water at 9.00 am. In each study, the
volunteers fasted overnight before administration of tizanidine and received a warm
meal 3 hours and light meals 7 and 10 hours afterwards.
The subjects were under direct, close medical supervision during the days of
administration of tizanidine. Fluids for intravenous infusion were available for
immediate use, but were not needed.
Table 3. Structure of Studies II, III and IV.
Study
No.
Study type Pretreatment medication in cross-over
studies or grouping variable in parallel
studies
Washout
period
(weeks)
Tizanidine oral
dose
II 2-phase
cross-over
fluvoxamine 100 mg x 1 for 4 days
placebo x 1 for 4 days (at 8.00 am)
4 4 mg on day 4 at
9.00 am
III 2-phase
cross-over
ciprofloxacin 500 mg x 2 for 2.5 days
placebo x 2 for 2.5 days
(at 8.00 am and 8.00 pm)
3 4 mg on day 3 at
9.00 am
IV parallel EE2 20 µg + GD 75 µg, 12 subjects
EE2 30 µg + GD 75 µg, 3 subjects
for at least 6 days (at 8.00 am)
Controls had no pretreatment
4 mg at 9.00 am
EE2; ethinylestradiol, GD; gestodene.
2.3. CYP1A2 activity assessment: caffeine test
To evaluate the possible association between CYP1A2 activity and tizanidine
pharmacokinetics, a caffeine test was performed on the day prior to each study day
(Fuhr et al. 1996, Spigset et al. 1999). The subjects ingested a 100 mg caffeine-tablet
at 9.00 am, after having abstained from caffeine intake for at least 12 hours, and a
blood sample for analysis of plasma caffeine and paraxanthine levels was taken from
each subject 6 hours after caffeine intake.
2.4. Blood and urine sampling
On the days of administration of tizanidine, a forearm vein of each subject was
cannulated with a plastic cannula and kept patent with an obturator. Timed blood
samples were drawn before the administration of tizanidine and at 20, 40, 60, and 90
min and 2, 3, 4, 5, 7, 9, 12, and 24 hours later. Blood samples (10 ml each) were
collected in ethylenediaminetetraacetic acid-containing tubes. Plasma was separated
by centrifugation within 30 min and stored at -70°C until analysis. Urine was
collected cumulatively in 2 fractions, 0 to 12 hours, and 12 to 24 hours. Urine
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volumes were measured and aliquots were taken from each fraction and stored at
-70°C until analysis.
2.5. Determination of plasma and urine drug concentrations
2.5.1. Tizanidine and tizanidine metabolites
In Study II, plasma tizanidine concentrations were quantified by use of Perkin-Elmer
(PE) SCIEX API 3000 liquid chromatography-tandem mass spectrometry. A Zorbax
SB-CN column (150 x 2.1 mm), and a mobile phase consisting of acetonitrile (60%),
10 mM ammonium acetate (pH 5.0 adjusted with glacial acetic acid; 20%), and 2-
propanol (20%) were used. The mass spectrometer was operated in the turbo ion
spray mode with positive ion detection, and plasma tizanidine was measured by Q1
single ion monitoring using the mass-to-charge ratio (m/z) value 254. This m/z value
represents the [M+H]+ ion for tizanidine. The limit of quantification was 0.04 ng/ml,
and the day-to-day coefficient of variation (CV) was 12.6% at 0.1 ng/ml and 9.4% at
1.0 ng/ml (n = 5). Fluvoxamine did not interfere with the determination of plasma
tizanidine.
In Studies III and IV, plasma tizanidine concentrations were quantified by use of PE
SCIEX API 3000 (Study III) and PE SCIEX API 2000 (Study IV) liquid
chromatography-tandem mass spectrometry systems. Chromatography was
performed on an XTerra RP C18 column (3.9 x 100 mm) using gradient elution. The
mobile phase consisted of 10 mM ammonium acetate (pH 9.5, adjusted with 25%
ammonia solution) and acetonitrile. The mass spectrometer was operated in the
atmospheric pressure chemical ionization mode with positive ion detection and the
ion transition monitored was m/z 254 to m/z 44 for tizanidine. In Study IV
tizanidine metabolites were also determined; the ion transitions monitored were m/z
268 to m/z 211 for M-3, m/z 228 to m/z 211 for M-4, m/z 252 to m/z 216 for M-5,
m/z 415 to m/z 286 for M-9, m/z 288 to m/z 188 for M-10 and m/z 230 to m/z 44 for
the internal standard, clonidine. In Study III, the limit of quantification for tizanidine
was 0.02 ng/ml and the day-to-day CV was 6.0% at 0.1 ng/ml, 3.2% at 1.0 ng/ml
and 4.5% at 10 ng/ml (n = 6). In Study IV, the limit of quantification for tizanidine
was 0.05 ng/ml, and the day-to-day CV was 17.4% at 0.1 ng/ml, 6.4% at 1.0 ng/ml
and 7.5% at 10 ng/ml (n = 8). A signal to noise ratio of 10:1 was used as the limit of
detection for tizanidine metabolites, and the quantities are given in arbitrary units
relative to the ratio of the peak height of the metabolite to the peak height of the
internal standard. Ciprofloxacin, ethinylestradiol or gestodene did not interfere with
the determination of plasma tizanidine.
2.5.2. Fluvoxamine
In Study II, the plasma concentrations of fluvoxamine were determined by HPLC
(Palego et al. 2000). The limit of quantification was 10 ng/ml, and the day-to-day
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CV was 4.2% at 18 ng/ml and 3.9% at 320 ng/ml (n = 4).
2.5.3. Ciprofloxacin
In Study III, the plasma concentrations of ciprofloxacin were determined by HPLC
(Maya et al. 2001). The limit of quantification was 0.1 mg/l, and the day-to-day CV
was 5.3% at 0.2 ng/ml, and 1.0% at 6.0 ng/ml (n = 4).
2.5.4. Caffeine and paraxanthine
In Studies II to IV, plasma caffeine and paraxanthine concentrations were
determined by HPLC, with ?-OH-ethyltheophylline as the internal standard (Pickard
et al. 1986, Holland et al. 1998). The day-to-day CV of caffeine and paraxanthine
was less than 6% at relevant concentrations.
2.6. Pharmacokinetic calculations
The pharmacokinetics of tizanidine and its metabolites M-3 and M-4 were
characterized by plasma Cmax, tmax, AUC(0-?), and t1/2. The terminal log-linear part
of the concentration-time curve was visually identified for each subject. The
elimination rate constant (ke) was determined with the use of linear regression
analysis of the log-linear part of the plasma concentration-time curve. The t1/2 was
calculated by the following equation: t1/2 = ln2/ke. The AUC values were calculated
by use of the linear trapezoidal rule for the rising phase of the plasma tizanidine
concentration-time curve and the log-linear trapezoidal rule for the descending
phase, with extrapolation to infinity, when appropriate, by division of the last
measured concentration by ke. The amount of tizanidine and its metabolites excreted
into the urine within 24 hours (Ae) was calculated. The renal clearance (CLrenal) of
tizanidine was calculated as Clrenal = Ae/AUC from 0 to 24 hours. The
pharmacokinetic parameters of fluvoxamine were characterized by Cmax and AUC(0-
25), i.e. the AUC from 0 to 25 hours after the last dose of fluvoxamine. The
pharmacokinetics of ciprofloxacin were characterized by Cmax and AUC(0-10), i.e.
the AUC from 0 to 10 hours after the last dose of ciprofloxacin. The
pharmacokinetic calculations were performed with the program MK-model, version
5.0 (Biosoft, Cambridge, UK).
2.7. Pharmacodynamic measurements
The pharmacodynamic variables were assessed before administration of tizanidine
and immediately after each blood sampling, up to 24 hours. The systolic and
diastolic blood pressures and heart rate were measured twice from the forearm with
the subject in a sitting position, and the mean value was used in the calculations. The
blood pressures and heart rates were measured with an automatic oscillometric blood
pressure monitor (HEM-711; Omron Healthcare GmbH, Hamburg, Germany).
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Before the study started, the volunteers were properly trained to perform three
psychomotor tests (Olkkola et al. 1994, Backman et al. 1996a, Lamberg et al. 1998).
DSST. The Digit Symbol Substitution Test has been demonstrated to be sensitive
for measuring both cognitive and motor effects of psychoactive drugs (Stone 1984).
In this test, the volunteer substitutes digits (1-9) for simple coded symbols. The
number of correctly substituted digits in 2 min was recorded.
Subjective drowsiness. Subjective drowsiness was evaluated on a 100-mm-long
horizontal visual analogue scale (VAS) with adjectives with opposite meanings at
both ends. In this test, the scale ranges from No drug effect to Maximal drug effect,
expressed in Finnish. The subject puts a mark on this scale as a self-rating of his or
her feelings at the moment.
Subjective drug effect. The performance of this test is identical to that for
subjective drowsiness, except that Alert and Drowsy are at the ends of the scale for
self-evaluation of subjective drowsiness.
For each pharmacodynamic variable, the incremental or decremental area under the
effect versus time curve from 0 to 12 hours [AUC(0-12 h)] was calculated by use of
the trapezoidal rule. In addition, the maximum responses in each pharmacodynamic
variable were recorded.
2.8. Statistical analysis
In Studies II and III, the pharmacokinetic and pharmacodynamic variables after the
two pretreatments were compared by repeated-measures analysis of variance with
treatment sequence as a factor or, in the case of tmax, with the Wilcoxon signed-rank
test. In Study IV, the pharmacokinetic and pharmacodynamic variables between the
groups were compared by the unpaired t-test or, in the case of tmax, with the Kruskal-
Wallis one-way analysis of variance. In Studies II to IV, 95% confidence intervals
(CI) were calculated for the mean differences of selected variables. The Pearson
correlation coefficient was used to investigate possible relationships between the
pharmacokinetic variables or plasma concentrations of tizanidine and the plasma
caffeine/paraxanthine concentration ratio or the measured pharmacodynamic
variables. All the data were analysed with the statistical program Systat for
Windows, version 6.0.1. (SPSS Inc, Chicago, IL, USA). The differences were
considered statistically significant when P was < 0.05.
2.9. Ethical considerations
All study protocols were conducted according to the revised Declaration of Helsinki
(WMA 2000), and were approved by the appropriate ethics committees according to
current regulations. The protocols of Studies II to IV were approved by the Ethics
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Committee for Studies in Healthy Subjects, Hospital District of Helsinki and
Uusimaa and the Finnish National Agency for Medicines. All subjects received both
oral and written information and gave their written informed consent before entering
the studies.
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RESULTS
1. Metabolism of tizanidine in vitro (Study I)
Incubation of 80 nM tizanidine with HLM resulted in time- and NADPH-dependent
substrate consumption, with a log-linear decline in tizanidine concentration until 45
min, a t1/2 of 50 min and an initial reaction velocity of 1.1 pmol/min/mg protein. The
chemical CYP1A2 inhibitors furafylline, fluvoxamine and ciprofloxacin caused
substantial inhibition of tizanidine metabolism, but no significant effect was
observed with selective inhibitors of isoforms other than CYP1A2. Percent of
inhibition of tizanidine (80 nM) metabolism by chemical CYP inhibitors after
incubation for 45 min is shown in Table 4. Recombinant CYP1A2 (30 pmol
CYP/ml) metabolised tizanidine to a substantial degree (35% in 45 min), but other
recombinant CYPs (30 pmol CYP/ml) had little (<5%) capacity for the drug.
Control supersomes did not metabolise tizanidine.
Table 4. Percent of inhibition of tizanidine metabolism in pooled HLM by inhibitors of different
CYP isoforms and percent of metabolism of tizanidine by different recombinant CYP enzymes.
Chemical inhibition of tizanidine metabolism
Target CYP  Inhibitor % inhibited
% metabolised by
recombinant CYP
CYP1A2 Furafylline 20 µM1,2 86% 35%
Furafylline 5 µM1,2 77%
Fluvoxamine 10 µM3 71%
Fluvoxamine 1 µM3 60%
Fluvoxamine 0.1 µM3 26%
Ciprofloxacin 200 µM4 31%
CYP2C8 Trimethoprim 100 µM5 2%
CYP2C9 Sulfaphenazole 10 µM1,2 8%
CYP2C19 Omeprazole 10 µM6 6% 5%
CYP2D6 Quinidine 10 µM2 0%
CYP2E1 Diethyldithiocarbamate 100 µM1,2 28% 3%
CYP3A4 Ketoconazole 1 µM1,2 13% 1%
Troleandomycin 100 µM2 11%
CYP3A5 3%
1Eagling et al. 1998, 2Newton et al. 1995, 3Brøsen et al. 1993, 4Fuhr et al. 1992, 5Wen et al. 2002,
6Ko et al. 1997.
The predicted in vivo hepatic clearance of tizanidine, using the well-stirred and
parallel-tube models, was close (68% and 82%, respectively) to its estimated hepatic
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clearance. The estimated 50% inhibitory concentration (IC50) value of fluvoxamine
was 0.7 µmol/l (223 µg/l), thus close to the therapeutic plasma concentration of
fluvoxamine (73 µg/l; Figgitt & McClellan 2000). In contrast, ciprofloxacin, at a
concentration (200 µM; 66 mg/l) more than 40-fold higher than its Cmax in humans
(1.5 mg/l; Dollery 1999), inhibited the metabolism of tizanidine in HLM by only
approximately 30%.
2. Effects of CYP1A2-inhibiting drugs on tizanidine pharmacokinetics and
pharmacodynamics in humans (Studies II to IV).
The CYP1A2-inhibiting drugs fluvoxamine, ciprofloxacin and OCs containing
ethinylestradiol and gestodene markedly increased the plasma concentration and
effects of tizanidine. The changes in tizanidine pharmacokinetic parameters are
shown in Figure 7, and the strong pharmacodynamic effects are shown in Figure 8.
2.1. Effects of fluvoxamine on tizanidine (Study II)
Pharmacokinetics of tizanidine (Figure 7). A 4-day pretreatment with
fluvoxamine 100 mg daily increased the mean AUC(0-?) of tizanidine 33-fold (P <
0.001) and the mean Cmax 12-fold (P < 0.001). In one subject, the AUC(0-?) of
tizanidine was increased up to 103-fold. In addition, the mean tizanidine t1/2 of all
patients was prolonged considerably, from 1.5 hours to 4.3 hours (P < 0.001).
Pharmacodynamics of tizanidine (Figure 8). During pretreatment with
fluvoxamine, the mean maximal reductions of the systolic and diastolic blood
pressures from baseline values were -48 mmHg and -32 mmHg, respectively. This
was significantly more than the corresponding reductions during the placebo phase
(-13 mmHg and -11 mmHg, respectively, P < 0.001). The reductions in blood
pressures were accompanied by a decrease in heart rate. During the fluvoxamine
phase, the subjects did not void during the first 6 hours after tizanidine intake even
though the hypotensive subjects were encouraged to drink water. In addition, in the
fluvoxamine phase the performance on the DSST was poorer, and subjective drug
effect and drowsiness were increased (P < 0.001). The changes from baseline in the
pharmacodynamic variables correlated significantly with the plasma concentrations
of tizanidine (P < 0.001).
Fluvoxamine concentrations. The AUC(0-25) and Cmax of fluvoxamine were 1199
± 293 ng h/ml and 72 ± 23 µg/l, respectively, and varied 2.3- and 2.8-fold between
the individual subjects.
2.2. Effects of ciprofloxacin on tizanidine (Study III)
Pharmacokinetics of tizanidine (Figure 7). Pretreatment with ciprofloxacin 500
mg twice daily for 2.5 days increased the mean AUC(0-?) of tizanidine 10-fold (P <
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0.001) and the mean Cmax 7-fold (P < 0.001). The mean t1/2 of tizanidine was
prolonged only slightly by ciprofloxacin, from 1.5 to 1.8 hours (P = 0.007).
Pharmacodynamics of tizanidine (Figure 8). During the ciprofloxacin phase, the
mean maximal reductions of the systolic and diastolic blood pressures from baseline
values were -35 mmHg and -24 mmHg, respectively. The corresponding reductions
during the placebo phase were only -15 mmHg and -11 mmHg, respectively, (P <
0.001). There was no significant difference in heart rate between the two phases.
The performance on the DSST was poorer and the subjective drug effect and
drowsiness were significantly increased in the ciprofloxacin phase. The changes
from baseline in the pharmacodynamic variables correlated significantly with the
plasma concentrations of tizanidine (P < 0.001).
Ciprofloxacin concentrations. The AUC(0-10) and Cmax of ciprofloxacin were 7.8
± 1.1 ng h/ml and 1.4 ± 0.2 mg/l, respectively, and varied 1.6- and 1.5-fold between
the individual subjects.
2.3. Effects of oral contraceptives containing ethinylestradiol and gestodene on
tizanidine (Study IV)
Pharmacokinetics of tizanidine (Figure 7). The mean AUC(0-?) of tizanidine was
4 times greater and the mean Cmax 3 times higher in the users of OCs (taking OCs
daily for 6 to 21 days immediately before tizanidine administration) than in the
control subjects (P < 0.001). In one of the OC users (7 days of OC use before
tizanidine administration) the AUC(0-?) of tizanidine exceeded nearly 20 times the
mean AUC(0-?) of the controls. There was no significant difference in mean
tizanidine t1/2 between the groups. In the three subjects with a higher ethinylestradiol
dose (30 µg) in their OCs, the Cmax and AUC(0-?) of tizanidine were similar to
those in the other OC users. The Ae of unchanged tizanidine was 4 times higher in
the OC users than in the controls (P = 0.008) but there was no difference in its renal
clearance between the groups (P = 0.85).
Pharmacokinetics of tizanidine metabolites. In the OC group, the mean t1/2 of M-3
was longer and the mean AUC(0-?) was greater than in the control group. The
AUC(0-?) and Cmax of M-4 were smaller in the OC users than in the controls. The
OC users had a 2 times higher plasma tizanidine/M-3 AUC(0-?) ratio and a 5 times
higher plasma tizanidine/M-4 AUC(0-?) ratio than the control subjects (P < 0.001).
The Ae of M-3 and M-10 were greater while the Ae of M-4 was smaller in the OC
users than in the controls. However, all tizanidine/metabolite (M-3, M-4, M-5, M-9,
M-10) excretion ratios in urine were higher in the OC users than in the controls (P <
0.05).
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Pharmacodynamics of tizanidine (Figure 8). In the OC users, tizanidine reduced
the mean maximal systolic and diastolic blood pressures from baseline values by -29
mmHg and -21 mmHg, respectively. The corresponding values were significantly
smaller in the control subjects; -17 mmHg and -13 mmHg, respectively (P < 0.01).
In addition, the subjective drug effect was significantly stronger in the OC users than
in the controls.
3. Relationship between tizanidine pharmacokinetics and the caffeine test
(Studies II to IV).
Fluvoxamine increased the plasma caffeine/paraxanthine ratio 12.5-fold (P = 0.002),
but ciprofloxacin increased it only 2.1-fold (P = 0.005). The AUC(0-?) of tizanidine
and its increase by fluvoxamine and ciprofloxacin correlated with the
caffeine/paraxanthine ratio and its increase, respectively (P < 0.03).
The mean plasma caffeine/paraxanthine ratio was 2.8 times higher in the OC users
than in the control subjects (P < 0.001). The caffeine/paraxanthine ratio correlated
significantly with, for example, the AUC(0-?), Cmax and Ae of tizanidine, and with
the tizanidine/M-3 and tizanidine/M-4 AUC(0-?) ratios. The caffeine/paraxanthine
ratio and the tizanidine AUC(0-?) correlated strongly with the urinary
tizanidine/metabolite (M-3, M-4, M-5, M-9) Ae ratios, while the correlations with
the tizanidine/M-10 Ae ratio were weaker.
Summarized relationships between the caffeine/paraxanthine ratio and tizanidine
AUC(0-?) in Studies II to IV are shown in Figure 9.
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Figure 7. Effect of fluvoxamine (Flu), ciprofloxacin (Cip), and oral contraceptives (OC)
containing ethinylestradiol and gestodene on pharmacokinetics of (4 mg) tizanidine in Studies II to
IV. Ratios of mean (bars) and individual values (dots) of tizanidine AUC(0-?), Cmax, and t1/2, and
caffeine/paraxanthine ratio, in the fluvoxamine or ciprofloxacin phases to their respective values
during placebo phases, in OC users to the mean control value (dashed line).
* P < 0.05
** P < 0.01
*** P < 0.001
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Figure 8. Pharmacodynamic variables; mean maximum changes ± SEM (standard error of the
mean) by tizanidine (4 mg) from baseline values (minimum or maximum) in systolic and diastolic
blood pressure, heart rate, and psychomotoric tests (digit symbol substitution test [DSST],
subjective drowsiness [VAS], and subjective drug effect [VAS]), after pretreatment with
fluvoxamine (Flu), ciprofloxacin (Cip), or oral contraceptives (OC) containing ethinylestradiol and
gestodene, and their respective control (Ctrl) values.
* P < 0.05
** P < 0.01
*** P < 0.001
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Figure 9. Relationships between the plasma caffeine/paraxanthine ratio and tizanidine AUC(0-?)
during control phases (Studies II and III) and in control subjects (Study IV), and between the fold
increase in plasma caffeine/paraxanthine ratio and tizanidine AUC(0-?), in the fluvoxamine (II) or
ciprofloxacin (III) phases to their respective values during placebo phases, in OC users (IV) to the
mean control value. Solid circles, fluvoxamine study (Study II); solid triangles, ciprofloxacin
study (Study III); open circles, OC study (Study IV).
Discussion
50
DISCUSSION
1. Methodological considerations
1.1. In vitro study
HLM and recombinant human CYP enzymes are suitable in vitro approaches for
drug metabolism and drug-drug interaction studies (Ring & Wrighton 2000), and
were used in Study I for identifying the CYP enzymes that catalyse the metabolism
of tizanidine. Our aim was to identify the CYP enzymes responsible for the total
elimination of tizanidine, rather than analysing different tizanidine metabolites.
Therefore, the disappearance of parent tizanidine was measured after its incubation
with HLM and recombinant CYP enzymes. To avoid interindividual variability in
CYP activities, pooled HLM were used since they more precisely represent the
population average than the use of a limited number of individual microsomal
samples. Recombinant CYP enzymes express only a single CYP isoform and are
useful in identifying the role of a specific CYP enzyme in the metabolism of a drug
or in a particular metabolic pathway. The concentration of microsomal protein and
the incubation time used were validated to be within the linear range for the initial
rate of tizanidine metabolism and within the loglinear part of tizanidine depletion,
respectively. Such linear conditions are necessary for proper in vitro studies, since
excessive binding due to high microsomal protein concentrations and excessive
incubation times may cause reduced concentration of the drug available for
metabolism or inhibition of the CYP mediated reaction.
As most drugs are poorly soluble in water, organic solvents are commonly needed to
dissolve them. Organic solvents can greatly affect the enzymatic activities of the
CYP isoforms (Chauret et al. 1998, Hickman et al. 1998). In our in vitro study, the
concentrations of methanol (< 0.5% v/v) and NaOH (0.01% w/v) were kept at a
minimum and did not affect the activity of the microsomes. In recombinant CYP
enzyme studies the final methanol concentration was 0.002% and had no effect on
CYP activities (Easterbrook et al. 2001). The incubation conditions, such as ionic
strength and the pH value of the incubation medium, may also influence the
outcome of in vitro studies (Venkatakrishnan et al. 2001). 0.1 M sodium phosphate
buffer (pH 7.4) was used as the incubation medium, which is similar to the ionic
strength and pH of hepatic cytoplasm in humans.
The use of relevant substrate concentrations is important in in vitro studies since the
contributions of different CYP isoforms may be greatly affected by the
concentration used (Lin & Lu 1997, Wang et al. 2000). The 80 nM (20.3 ng/ml)
concentration of tizanidine (molecular weight 253.72) used in Study I is roughly at
the same level as the reported peak plasma concentrations in humans (mean Cmax
after administration of a single dose of 8 mg tizanidine was 25.8 ng/ml in patients
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with spinal cord injury, Mathias et al. 1989). However, the relationship between the
plasma concentration of a drug and its concentration at the enzyme active site in a
hepatocyte is not straightforward. Consequently, the use of a single, low substrate
concentration can be misleading if, for example, enzyme kinetics in vitro are
atypical (for example sigmoidal), and thus causes limitations in the interpretation of
results. The chemical inhibitors and their concentrations used in Study I were chosen
according to previous publications and they are well-established in in vitro studies
(Fuhr et al. 1992, Brøsen et al. 1993b, Newton et al. 1995, Ko et al. 1997, Eagling et
al. 1998, Wen et al. 2002).
This study could have been improved by determining the formation of tizanidine
metabolites by the different CYP enzymes. However, our aim was not to study
detailed enzyme kinetics over a wide range of substrate concentrations or to identify
all enzymes that contribute to the particular metabolic pathways. We aimed to gain
information about the role of CYP enzymes in tizanidine metabolism at clinically
relevant concentrations, in order to examine the need for further in vivo interaction
studies.
1.2. In vivo studies
Studies II and III were randomized, cross-over studies in design. Each subject served
as his own control, minimizing the effect of interindividual variability and reducing
the number of subjects needed (10) to find a possible clinically significant
interaction. Balanced randomization and adequate washout periods (3 to 4 weeks)
minimized the risk for possible period effects and carry-over effects, respectively.
Only male subjects were chosen in Studies II and III, to avoid possible effects of
menstrual cycle phases or sex on tizanidine pharmacokinetics (Rasmussen et al.
2002, Faber et al. 2005).
Study IV was an open parallel group study with 15 females using OCs and 15
females taking no concomitant medication. Since different female sex-steroids have
different propencities to interact with CYP enzymes (Back et al. 1991b, Laine et al.
2003), all the OC-using subjects chosen for this study used a preparation containing
the same estrogen (ethinylestradiol) and progesterone (gestodene) component. The
OC users had been using their OC preparation for at least 1 cycle before the study,
and for 6 to 21 days immediately before the study day. The controls were in a
corresponding phase of their menstrual cycles.
All the subjects were young, healthy volunteers. None of the subjects were tobacco
smokers, since smoking can induce CYP1A2 activity. Use of other drugs was
forbidden for 2 weeks before each study day. Grapefruit juice, an inhibitor of
CYP3A4, was prohibited for 1 week before the study. Alcohol use and drinks
containing caffeine were not allowed for 2 days before the study days. The possible
effect of food on the pharmacokinetics (for example absorption) or
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pharmacodynamics (for example sedative effects) of tizanidine was lessened by a
fasting period before drug intake and by serving standard meals after drug intake.
Charcoal-broiled meat and cruciferous vegetables were not strictly forbidden in this
study, since their CYP1A2 inducing effects are only modest (Harris et al. 2003,
Larsen & Brøsen 2005) Furthermore, country of residence and ethnic origin can
influence CYP1A2 and CYP3A4 activity (Tantcheva-Poor et al. 1999, Yu et al.
2001). All subjects in this study were Finnish residents and of Caucasian origin.
In these studies, clinically relevant doses of the different drugs were used. The t1/2 of
fluvoxamine is 7 to 60 hours (in Study II, the longest t1/2 was 28 hours), of
ciprofloxacin 3 to 4 hours, and of ethinylestradiol and gestodene of the order of 24
hours. Since the pretreatment period for fluvoxamine was 4 days, for ciprofloxacin
2.5 days and for the OC users 6 to 21 days prior to tizanidine administration, plasma
concentrations of fluvoxamine, ciprofloxacin, ethinylestradiol and gestodene were at
clinically relevant levels on the study days (Jung-Hoffmann & Kuhl 1990, Dollery
1999). However, because ethinylestradiol induces the formation of SHBG, to which
gestodene binds, concentrations of total plasma gestodene can continue to increase
for the whole cycle (Jung-Hoffmann & Kuhl 1990, Dollery 1999). In any case, in
Study IV, there was no significant correlation between the day of OC use (range
from 6 to 21 days) and the caffeine/paraxanthine ratio or the pharmacokinetic
variables of tizanidine. In the three women who used a higher dose of
ethinylestradiol (30 µg), the caffeine/paraxanthine ratios and tizanidine
concentrations were not higher than in the other OC users. Furthermore, there were
no differences in the extent of interaction between women using different brands of
oral contraceptives. However, since the OC preparations used in this study contained
only ethinylestradiol and gestodene, the findings can not be directly generalized to
OCs containing other estrogens or progesterones.
To evaluate the possible association between CYP1A2 activity in vivo and
tizanidine pharmacokinetics, a caffeine test was performed 1 day prior to tizanidine
administration. The formation of paraxanthine from caffeine is mediated by
CYP1A2 (Fuhr et al. 1996, Spigset et al. 1999). The subjects abstained from
caffeine intake for at least 12 hours before intake of 100 mg caffeine, and a blood
sample for analysis of plasma caffeine and paraxanthine was taken 6 hours after
caffeine intake. The subjects were asked to report if any caffeine intake during the
prohibited period had happened by mistake, but this may be problematic with regard
to reliability.
Pharmacodynamic effects were measured to complement tizanidine pharmacokinetic
results and to investigate the possible clinical relevance of the interactions. Blood
pressure and heart rate were measured twice from the forearm with the subjects in a
sitting position, and mean values were used in the calculations. The subjective and
psychomotoric effects of tizanidine were measured by three tests validated and
widely used for these purposes. Before entering the studies, the volunteers were
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trained to properly perform the tests. The blood pressures of the subjects were
frequently measured and the subjects were under direct, close medical supervision
during the days of tizanidine administration. The subjects were encouraged to drink
water, and fluids for intravenous infusion were available for immediate use but were
not needed.
2. Elimination of tizanidine by CYP enzymes in vitro
The CYP enzymes involved in the metabolism of tizanidine were not known at the
time this study began. Our aim in Study I was to identify the contribution of
different CYP enzymes to the total elimination of tizanidine in vitro. A time- and
NADPH-dependent log-linear decline in tizanidine concentration was detected when
tizanidine was incubated with HLM. Furthermore, the predicted in vivo hepatic
clearance, using the well-stirred and parallel-tube models, was close to its estimated
actual in vivo hepatic clearence, suggesting that the elimination of tizanidine is
mainly CYP-dependent.
Furafylline is a potent and selective mechanism-based inhibitor of CYP1A2 at the
concentrations (5 and 20 µM) used in this study (Newton et al. 1995, Eagling et al.
1998); a strong inhibition of tizanidine metabolism was achieved at both
concentrations. Fluvoxamine is also a potent, albeit nonselective, inhibitor of
CYP1A2; the previously reported IC50 of fluvoxamine for inhibition of O-
deethylation of phenacetin was 0.2 µM (Brøsen et al. 1993b). In the present study,
fluvoxamine caused a concentration-dependent inhibition of tizanidine metabolism
with an estimated IC50 value of 0.7 µM. However, at the concentrations used (up to
10 mM), fluvoxamine can inhibit also CYP2C9, CYP2C19, CYP3A4 and CYP2D6
(Hemeryck & Belpaire 2002). Ciprofloxacin (200 µM) inhibited tizanidine
metabolism by 31%. This is in agreement with previous studies indicating that
ciprofloxacin is only a moderately potent CYP1A2 inhibitor; 500 µM of
ciprofloxacin has decreased the activity of CYP1A2 by 70% (Fuhr et al. 1992).
Diethyldithiocarbamate is primarily used as an inhibitor for CYP2E1, but it also
inhibits CYP1A2 by approximately 30% at the concentration (100 µM) used in our
study (Eagling et al. 1998). This might explain the present finding that tizanidine
metabolism was inhibited by 28% by DDC. Inhibitors specific to other CYP
isoforms had no substantial effects on tizanidine metabolism.
Recombinant human CYP1A2 isoform caused a 35% reduction in parent tizanidine
concentration after incubation for 45 min. The decline in tizanidine concentration
observed with recombinant CYP1A2 was almost as rapid as that achieved with
HLM. Of the other recombinant isoforms tested (CYP2C19, CYP2E1, CYP3A4 and
CYP3A5), CYP2C19 diminished the concentration of tizanidine by approximately
5%, while the other isoforms had an even more negligible impact.
Our in vitro findings stongly suggested that human CYP1A2 is primarily responsible
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for the metabolism of tizanidine, and revealed a possibility for clinically important
pharmacokinetic drug interactions with tizanidine. For example, the average plasma
concentration of fluvoxamine during daily dosages of 100 mg is 24 ?g/l to 163 µg/l
(Niemi et al. 2001), which is similar to the approximated IC50 of fluvoxamine (0.7
µM; 223 µg/l) for tizanidine metabolism in our study. However, ciprofloxacin
inhibited tizanidine metabolism in HLM by only approximately 30%, even though
its concentration was approximately 40-fold higher than its Cmax in humans (Dollery
1999). Accordingly, we found it important to investigate the effects of CYP1A2-
inhibiting drugs on tizanidine pharmacokinetics and pharmacodynamics in humans.
3. Effect of CYP1A2 inhibitors on tizanidine pharmacokinetics and the caffeine
test in humans
Fluvoxamine increased the AUC(0-?) of tizanidine 33-fold and the Cmax of
tizanidine 12-fold compared to placebo, with even much stronger effects in some
subjects. After ciprofloxacin, the AUC(0-?) and Cmax of tizanidine were increased
by 10-fold and 7-fold, respectively. These effects were seen in every subject
although the extent of the interactions varied substantially between individuals.
Women using OCs had 4 times greater AUC(0-?) and 3 times higher Cmax values
than the control subjects. Only fluvoxamine markedly prolonged the t1/2 of
tizanidine; ciprofloxacin and OCs had only marginal effects.
The possible associations between the plasma caffeine/paraxanthine ratio and
tizanidine pharmacokinetics were evaluated in Studies II, III and IV. Significant
correlations were found between the control values of tizanidine AUC(0-?) and the
caffeine test results, as well as their increases by fluvoxamine, ciprofloxacin and
OCs. This supports the role of CYP1A2 in the metabolism of tizanidine, and the
inhibition of CYP1A2 by fluvoxamine, ciprofloxacin and OCs as the mechanism of
their pronounced interactions with tizanidine.
Even though the effects of fluvoxamine and ciprofloxacin on tizanidine AUC(0-?)
and Cmax values were seen in every subject, and the majority of the OC users had
higher AUC(0-?) and Cmax values than the highest values of the control subjects,
there were prominent variations between the individuals. Due to the low oral
bioavailability of tizanidine, inhibition of the presystemic metabolism of tizanidine
may lead to very strong interaction potentials in certain individuals. For example,
fluvoxamine increased the tizanidine AUC(0-?) 103-fold in one subject but only 14-
fold in another. The effect of ciprofloxacin on the tizanidine AUC(0-?) ranged from
6-fold to 24-fold. The greatest individual value of tizanidine AUC(0-?) in the OC
group exceeded nearly 20-fold the mean tizanidine AUC(0-?) in the control group.
Thus, in susceptible individuals the effect of OCs and tizanidine combined can be
considerably greater than what can be inferred from the tizanidine product
information, assuming a 50% reduction in tizanidine clearance by OCs. There was a
fair amount of overlap between the OC and control groups. Variability was also
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observed in the caffeine test results, both in controls and after premedications. These
interindividual variations could be explained by variations in CYP1A2 activity,
governed mainly (73%) by genetic factors (Rasmussen et al. 2002), which makes
prediction of individual tizanidine response difficult. Theoretically, SNP´s such as
CYP1A2*1F might explain the large interindividual variation in tizanidine
pharmacokinetics and caffeine test results, but CYP1A2 polymorphism
identification was beyond the scope of this study. Other factors affecting CYP1A2
activity, such as age, race and exposure to inducers or inhibitors (for example food)
could also modify the interaction. Furthermore, men have been reported to have
higher CYP1A2 activity than women (Meibohm et al. 2002, Rasmussen et al. 2002).
However, tizanidine pharmacokinetics and the caffeine/paraxanthine test results
were similar in the 20 male subjects during control phases in Study II and III, and
the 15 female subjects not using OCs in Study IV.
Fluvoxamine increased the caffeine/paraxanthine ratio 12.5-fold, and prolonged the
t1/2 of tizanidine from 1.5 hours during placebo to 4.3 hours. In contrast,
ciprofloxacin increased the caffeine/paraxanthine ratio only 2-fold and affected
tizanidine t1/2 marginally (from 1.5 hours to 1.8 hours). Also the effect of OCs on t1/2
of tizanidine was small, with no statistically significant difference observed between
the groups. The caffeine/paraxanthine ratio was approximately 3 times higher in the
OC users than in the control subjects. Thus, the effect of ciprofloxacin and OCs on
the systemic elimination of tizanidine (and caffeine) was insignificant, whereas their
effects on the CYP1A2-mediated presystemic metabolism were considerable, as
reflected by tizanidine AUC(0-?) and Cmax. As tizanidine was ingested 1 hour after
ciprofloxacin and the OCs, the pronounced effect on the presystemic metabolism
could be explained by high concentrations of ciprofloxacin and
ethinylestradiol/gestodene in the gastrointestinal wall and the liver during tizanidine
absorption. On the other hand, both ciprofloxacin and OCs are weaker CYP1A2
inhibitors than fluvoxamine, and ciprofloxacin has a shorter t1/2 (3 to 4 hours) than
fluvoxamine (7 to 60 hours) (Dollery 1999). These properties may explain the lack
of major effects of ciprofloxacin and OCs on the t1/2 of tizanidine and the caffeine
test. Furthermore, fluvoxamine inhibits the activity of CYP enzymes other than
CYP1A2, that is CYP2C9, CYP2C19, CYP2D6, CYP3A4, and, theoretically, this
could also contribute to its stronger effects on tizanidine pharmacokinetics.
Tizanidine undergoes significant presystemic metabolism, and has been reported to
have an oral bioavailability of 20% to 40% (Tse et al. 1987, Zanaflex product
information). However, as tizanidine was not given intravenously (Tse et al. 1987),
the exact value is not known. Since ciprofloxacin increased the Cmax of tizanidine by
7-fold, with a marginal effect on its t1/2, and fluvoxamine increased the Cmax by 12-
fold, the oral bioavailability of tizanidine obviously averages less than 20%, perhaps
around 5% to 15%, at least in young male subjects.
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Fluvoxamine has previously increased the plasma concentrations of several drugs
metabolised by CYP1A2, such as tacrine, clozapine, ropivacaine, theophylline and
caffeine (Becquemont et al. 1997, Chang et al. 1999, Jokinen et al. 2000, Yao et al.
2001, Christensen et al. 2002). However, the effect of fluvoxamine on tizanidine is
by far the strongest drug-drug interaction reported for CYP1A2 substrates. In our in
vitro study (Study I), fluvoxamine inhibited the metabolism of tizanidine with an
IC50 value close to the therapeutic plasma concentration of fluvoxamine. Thus, the in
vivo results fit well with the results obtained in vitro. In contrast, even at high
concentrations ciprofloxacin only moderately inhibited the elimination of tizanidine
in vitro. The ciprofloxacin-tizanidine interaction in humans is the strongest reported
drug interaction involving ciprofloxacin, since ciprofloxacin has increased the AUC
of theophylline, caffeine, clozapine and ropivacaine less than 2-fold (Wijnands et al.
1986, Harder et al. 1988, Batty et al. 1995, Raaska & Neuvonen 2000, Jokinen et al.
2003). The markedly increased tizanidine bioavailability after pretreatment with
drugs inhibiting CYP1A2 activity can probably be explained by the strong inhibition
of tizanidine presystemic metabolism.
In previous reports, OCs have reduced the clearance of theophylline, caffeine and
antipyrine by 30% to 55% in humans but the Cmax of caffeine and theophylline has
remained unaffected (Tornatore et al. 1982, Roberts et al. 1983, Abernethy et al.
1985, Balogh et al. 1991, Pazzucconi et al. 1991, Balogh et al. 1995). Unexpectedly,
women using OCs containing ethinylestradiol and gestodene or levonorgestrel have
had 10 to 20 times higher serum concentrations of selegiline than women without
concomitant medications (Laine et al. 1999). The authors concluded that the
mechanism of the interaction may be inhibition of the CYP-mediated N-
demethylation of selegiline to desmethylselegiline by OCs. Later, it was suggested
that CYP1A2 is, at least partly, responsible for this metabolic pathway in humans
(Kivistö et al. 2001). It is not clear whether it is the estrogen or progesterone
component in the OC preparation used in Study IV that inhibits CYP1A2 and thus
increases the plasma concentrations of tizanidine. Gestodene is a potent CYP3A4
inhibitor in vitro (Guengerich 1990a, Laine et al. 2003), but it has had no effect on
CYP1A2 in vitro at concentrations even 10 000 times higher than the therapeutic
concentration in plasma (Guengerich 1990a). The effect of ethinylestradiol on
CYP1A2 activity has been only poorly investigated in vitro. However, CYP1A2
participates in the biotransformation of ethinylestradiol to its main metabolite 2-
hydroxy-ethinylestradiol, together with CYP3A4 and CYP2C9 (Wang et al. 2004).
There are a number of substrates that have been studied and applied for phenotyping
of CYP1A2 (Faber et al. 2005). Caffeine has no presystemic metabolism (Dollery
1999), therefore its clearance principally reflects systemic elimination by CYP1A2.
Some consideration has been given to using theophylline as a probe for systemic
CYP1A2 activity. However, potential analytical sensitivity problems and safety
considerations suggest that theophylline has no advantage over caffeine for this
purpose (Rasmussen & Brøsen 1997). Furthermore, the O-de-ethylation of
Discussion
57
phenacetin is CYP1A2-mediated, and a breath test with 14C-labeled phenacetin has
been used for evaluating hepatic function (Breen et al. 1984). However, due to the
renal side effects of phenacetin following chronic dosing, its use is no longer
approved and therefore further studies of the use of phenacetin as a CYP1A2 probe
are unlikely. Tizanidine could also be a sensitive probe drug for studying CYP1A2
activity in humans both in baseline conditions and after potential inhibitors of
CYP1A2. The Cmax and AUC of tizanidine, a high extraction drug, seem to
(inversely) reflect mainly presystemic CYP1A2 activity. However, the use of
tizanidine as a probe drug in humans may be restricted by its unpleasant
pharmacodynamic effects. Recently, it has become evident that the pituitary
hormone melatonin is a selective substrate for CYP1A2 and thus might be used as a
rather non-toxic probe for CYP1A2 (Facciola et al. 2001, Härtter et al. 2001). Like
tizanidine, melatonin also has extensive presystemic metabolism (Härtter et al.
2001), and it would therefore be interesting to compare tizanidine and melatonin
pharmacokinetics in humans, as well as their behaviour in vitro.
4. Formation of tizanidine metabolites
Tizanidine is biotransformed to several metabolites (for example M-3, M-4, M-5,
M-9, and M-10) (Figure 1). M-3 and M-4 (formed from M-3) are the main
metabolites in plasma and urine (Koch et al. 1989). In Study IV, the amounts of
some of the tizanidine metabolites in plasma and urine were determined in arbitrary
units. In the OC users, the excretion of M-3 into urine was greater, while that of M-4
was smaller, than in the control subjects. Furthermore, the t1/2 and AUC(0-?) of M-3
were greater, and the Cmax of M-4 smaller, in the OC users than in the control
subjects. This suggests that the formation of M-4 from M-3 was inhibited in the OC
users.
The formation of all metabolites seems to be inhibited by the OCs, as the
tizanidine/metabolite ratios in plasma (M-3, M-4) and urine (M-3, M-4, M-5, M-9,
M-10) were 2 to 10 times higher in the OC users than in the controls. However, the
CYP enzymes that mediate the formation of different metabolites are not known in
detail. CYP1A2 seems to be important in the formation of metabolites M-3, M-4, M-
5 and M-9, because there were significant correlations between the
caffeine/paraxanthine ratio or tizanidine AUC(0-?) and the tizanidine/metabolite
ratios in plasma (M-3 and M-4) and urine (M-3, M-4, M-5, M-9). However,
CYP1A2 may not be crucial for the formation of M-10, as correlation between the
caffeine/paraxanthine ratio and the urine tizanidine/M-10 Ae ratio was weaker. In
order to exactly identify the CYP enzymes responsible for the formation of the
different metabolites, in vitro studies with HLM and recombinant CYP enzymes
should be performed. The use of tizanidine as a probe substrate for CYP1A2 activity
also requires careful determination of the CYP enzymes that contribute to the
formation of the different metabolites.
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5. Clinical implications
Ingestion of 4 mg tizanidine in young, normotensive, healthy male subjects resulted,
within 1 to 2 hours, in a mean minimum systolic/diastolic blood pressure of 79/46
mmHg and 90/55 mmHg during fluvoxamine and ciprofloxacin phases, respectively.
The corresponding minimum values during placebo phases in these studies were
115/66 mmHg and 122/76 mmHg, respectively. For OC users the mean blood
pressures decreased from 118/77 mmHg at baseline to 89/56 mmHg after tizanidine
ingestion, which was more than the corresponding reductions for the female control
subjects (from 116/73 mmHg to 99/59 mmHg). Due to the varying individual
tizanidine responses, co-segregating inversely with individual CYP1A2 activity, the
reductions can be even more pronounced in some subjects; the blood pressure of one
volunteer decreased from 112/74 mmHg at baseline to 63/43 mmHg after ingestion
of fluvoxamine and tizanidine. In the OC user whose AUC of tizanidine was nearly
20 times greater than the mean AUC in the controls, the blood pressure fell from
111/74 mmHg to 79/47 mmHg with tizanidine.
Concurrent use of tizanidine with fluvoxamine or ciprofloxacin resulted in
noticeable somnolence and dizziness, which lasted for 3 to 6 hours after tizanidine
administration. Muscle weakness and dry mouth were also reported. Furthermore,
the subjects had difficulties in concentrating on the psychomotoric test, as their
performance in the DSST was poorer than during placebo phases. The greatly
increased pharmacodynamic effects can considerably impair psychomotoric function
and reduce the capability to perform tasks that require skills (for example, driving a
vehicle).
These pharmacodynamic effects were caused by high tizanidine plasma
concentrations, since fluvoxamine, ciprofloxacin or the OC preparations had no
effects on the pharmacodynamic parameters compared with placebo when measured
at baseline, before administration of tizanidine. Furthermore, there were highly
significant correlations between the plasma concentrations of tizanidine and the
changes from baseline in the pharmacodynamic variables.
The mechanism of action of tizanidine is closely related to that of the
antihypertensive agent clonidine. As with clonidine, patients using tizanidine may
develop some adaptation to the pharmacodynamic effects within days of treatment
initiation, and may experience rebound hypertension after cessation of long-term
treatment with high doses (Zanaflex product information). A sudden withdrawal of
clonidine can cause rebound hypertension, due to overactivity of the sympathetic
nervous system (Geyskes et al. 1979). Accordingly, if tizanidine and a CYP1A2-
inhibiting drug were used concurrently for a longer period adaptation might
somewhat lessen the effects of tizanidine, but because the concentrations of
tizanidine are high an abrupt withdrawal of tizanidine (or the CYP1A2 inhibitor)
would probably lead to unusually severe rebound symptoms. There seem to be no
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published studies concerning possible rebound hypertension after sudden cessation
of chronic tizanidine treatment, but it is probably advisable that after receiving high
tizanidine doses or tizanidine concomitantly with a CYP1A2 inhibitor for a long
period of time, the dose should be decreased slowly to minimize the risk of rebound
hypertension.
Tizanidine is a widely used drug in, for example, Europe and the United States. In
Finland, during the year 2004, the daily consumption of tizanidine was 1.83 defined
daily doses (DDD)/1000 inhabitants (DDD for tizanidine, 12 mg/day). OCs are used
by approximately 100 million women world-wide for birth control. For fluvoxamine
the daily consumption was 0.58 DDD/1000 inhabitants (DDD for fluvoxamine is
100 mg/day), and that of ciprofloxacin was 0.56 DDD/1000 inhabitants (DDD for
ciprofloxacin, 1 g/day) during 2004 (Finnish Statistics on Medicines 2004). Since
different types of pain syndromes are not uncommon in patients with indications for
SSRI antidepressants (for example fibromyalgia), the combined use of fluvoxamine
and tizanidine is probably not unlikely. According to the National Agency for
Medicines and Social Insurance Institution in Finland, during a period of 3 months
(December 2003 to February 2004) 42 000 Finnish inhabitants had received
reimbursement for tizanidine, and 3 500 inhabitants for fluvoxamine. During this
period, 75 persons had concomitantly acquired tizanidine and fluvoxamine from the
pharmacy.
The clinical significance of the interactions with tizanidine and CYP1A2-inhibiting
drugs is obvious, since high tizanidine plasma concentrations can result in severe
systolic and diastolic hypotension, bradycardia, somnolence, dizziness and reduced
psychomotoric performance. The therapeutic range of tizanidine is narrow, the
concentration-effect relationship steep, and the individual response to a given dose
rather difficult to predict in advance. Only a single 4 mg dose of tizanidine was
administered in these studies; ingestion of tizanidine at higher doses, or twice or 3
times daily, concomitantly with CYP1A2-inhibiting xenobiotics, could cause even
stronger interactions. Additionally, higher doses of fluvoxamine or ciprofloxacin
might cause stronger tizanidine effects than those reported in these studies. The
subjects in these studies were healthy and young; it is possible that the effects are
even greater, for example, in elderly and infirm individuals, such as patients with
spasticity or pain syndromes. Age seems to have an effect on CYP-mediated drug
metabolism (Kinirons & Crome 1997, Tanaka 1999), and care must be taken when
extrapolating the results for elderly subjects or children. Among young adults and
the elderly (age range 20 to 70 years), the differences in CYP content and activity
seem, however, to be relatively small (± 16% of the level during the third decade)
(Shimada et al. 1994, Sotaniemi et al. 1997). However, elderly subjects who, for
example, have an increased risk of heart and brain ischemia are even more
vulnerable than young healthy subjects to the severe pharmacodynamic effects due
to high tizanidine plasma concentrations observed in this study. Momo et al. (2004)
reported one case in which an elderly Japanese woman presented several adverse
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symptoms (low heart rate, low body temperature, dry mouth and anuresis) when
concomitantly using fluvoxamine for depression and tizanidine for leg pain.
Our results have led to important changes in the clinical use of tizanidine. For
example, the manufacturer (Novartis) of tizanidine (Sirdalud®), has updated their
tizanidine product information on the basis of our study results; it now states that the
concurrent use of tizanidine and fluvoxamine is contraindicated and that care should
be exercised when tizanidine is used with other CYP1A2-inhibiting drugs.
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CONCLUSIONS
The following conclusions can be drawn on the basis of the results from Studies I to
IV:
1. Tizanidine is mainly metabolised by CYP1A2 in vitro; chemical inhibitors of
CYP1A2 inhibit elimination of tizanidine in HLM and recombinant CYP1A2
metabolises tizanidine to a substantial degree, while other CYP isoforms have
minimal effects.
2. Fluvoxamine drastically increases the plasma concentrations and effects of
tizanidine by inhibiting its presystemic and systemic elimination in humans. Their
concomitant use may cause serious adverse effects in patients.
3. Ciprofloxacin and OCs containing ethinylestradiol and gestodene greatly increase
the plasma concentrations and blood pressure-decreasing effect of tizanidine,
probably by inhibiting the CYP1A2-mediated presystemic metabolism of tizanidine.
4. In humans, tizanidine pharmacokinetics correlate well with CYP1A2 activity, as
assessed by the caffeine test, confirming that tizanidine is a CYP1A2 substrate also
in vivo.
5. Tizanidine could be a useful probe for studying presystemic CYP1A2
metabolism.
6. Concomitant use of fluvoxamine and tizanidine should be avoided, and care
should be exercised when tizanidine is used concomitantly with other inhibitors of
CYP1A2, such as ciprofloxacin or OCs containing ethinylestradiol and gestodene.
Acknowledgements
62
ACKNOWLEDGEMENTS
This work was carried out at the Department of Clinical Pharmacology, University of
Helsinki, during the years 2002-2005. I am grateful to all who helped me during this
period.
I especially express my sincere gratitude to:
Professor Pertti Neuvonen, for his unfailing support and encouraging supervision. His
dedication to the field of clinical pharmacology and to his undergraduates is unique and
extremely impressive. He always had time for me whenever I needed it.
Docent Janne Backman, my other supervisor, for his patient teaching of pharmacokinetics
and statistics, and his advice in designing and executing scientific studies. I deeply admire
his wide knowledge of the field.
Words can not express how thankful I am to my two wonderful supervisors. It is a
priviledge to have been a member of this excellent research group.
Professor Hannu Raunio and professor Kari Laine for their prompt and constructive
reviews of this thesis.
Jouko Laitila and Mikko Neuvonen for their skillful mass spectrometric determinations of
drug concentrations and supervision in the in vitro studies. Eija Mäkinen-Pulli, Kerttu
Mårtensson and Lisbet Partanen for their skillful technical assistance and readiness to
stretch their timetables according to the needs arising during study periods. I also thank
them for good company during the study days and in the laboratory. This work would not
have been possible without their efforts.
All my colleagues and co-workers at the Department of Clinical Pharmacology for their
help, friendship and wonderful times spent together: Kati Ahonen, Samuel Fanta, Hanna
Fredrikson, Tiina Jaakkola, Laura Juntti-Patinen, Mika Jokinen, Marjo Karjalainen, Jari
Lilja, Heli Malm, Marja Pasanen, Kari Raaska, Aleksi Tornio, Jung-Sheng Wang and Xia
Wen. Lauri Kajosaari, my room-mate, for his friendship and for being my personal
computer help desk. Carl Kyrklund, for his friendship and invaluable advices. Mikko
Niemi, for always having time and patience with my stupid questions. Furthermore, I am
grateful to Tuija Itkonen for her help in many practical matters. Each of you are thanked
for your unique personalities and for stimulating discussions, sometimes even concerning
work issues.
Jouni Ahonen for his support and co-authorship in study II.
Docent Kalle Hoppu and the staff of the Poison Information Centre.
This work was financially supported by the Clinical Drug Research Graduate School, the
Helsinki University Central Hospital Research Fund, the National Technology Agency of
Acknowledgements
63
Finland (TEKES), the Finnish Medical Society Duodecim, Sigrid Jusélius Foundation,
Finska Läkaresällskapet, Nylands Nation, the Orion Research Foundation, Stiftelsen
Dorothea Olivia, Karl Walter och Jarl Walter Perkléns Minne, and Wilhelm och Else
Stockmanns Stiftelse, all of which are gratefully acknowledged.
My friends in and outside medical school; I truly appreciate your friendship and times
spent together. I hope these general words suffice; no one mentioned – no one forgotten.
The Schröder´s “mafia”; Tom and Maria, Jim and Eeva, Maj-mommo, Eva-famo, Ville and
Sini, Anna and Kimppa and their children Alex, Eddie and Beni, and everybody else.
Thank you for your support and for welcoming me so warmly to your family. And Niki,
for your emboldening tail-wagging and unconditional love.
My family; Äiti, for always being my best friend. Mårten, for your support and for always
looking after your younger sister. Pappa, Michaela, Mirja and Jacob, for always being there
for me. Farfar and Farmor, for your caring assistance and home-made first-class dinners.
All my relatives and friends of all ages. Thank you all for making me who I am and for
always being uncritically proud of me.
Finally, my dearest soon-to-be-husband Ola, thank you for being you and for being it in my
life, independent of the dust in the corners at home. Amor vincit omnia.
Helsinki, November 2005
Marika Granfors
References
64
REFERENCES
Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose
oestrogen-containing oral contraceptives. Eur J Clin Pharmacol 1985;28:425-8.
Aklillu E, Carrillo JA, Makonnen E, Hellman K, Pitarque M, Bertilsson L, Ingelman-
Sundberg M. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and
expression: characterization of novel haplotypes with single-nucleotide polymorphisms in
intron 1. Mol Pharmacol 2003;64:659-69.
Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of
debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol
1990;39:533-7.
Bachmann K, White D, Jauregui L, Schwartz JI, Agrawal NG, Mazenko R, Larson
PJ, Porras AG. An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib
using theophylline as a CYP1A2 probe. J Clin Pharmacol 2003;43:1082-90.
Back DJ, Rogers SM. Review: first-pass metabolism by the gastrointestinal mucosa.
Aliment Pharmacol Ther 1987;1:339-57.
Back DJ, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole,
fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver
microsomes. Br J Clin Pharmacol 1991a;32:624-6.
Back DJ, Houlgrave R, Tjia JF, Ward S, Orme ML. Effect of the progestogens,
gestodene, 3-ketodesogestrel, levonorgestrel, norethisterone and norgestimate on the
oxidation of ethinyloestradiol and other substrates by human liver microsomes. J Steroid
Biochem Mol Biol 1991b;38:219-25.
Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma
concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996a;59:7-13.
Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ. Concentrations and
effects of oral midazolam are greatly reduced in patients treated with carbamazepine or
phenytoin. Epilepsia 1996b;37:253-7.
Backman JT, Kivistö KT, Olkkola KT, Neuvonen PJ. The area under the plasma
concentration-time curve for oral midazolam is 400-fold larger during treatment with
itraconazole than with rifampicin. Eur J Clin Pharmacol 1998;54:53-8.
Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases
plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002;72:685-91.
Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. 1998.
Br J Clin Pharmacol 2004;58:S831-43.
References
65
Balogh A, Irmisch E, Wolf P, Letrari S, Splinter FK, Hempel F, Klinger G, Hoffmann
A. [Effect of levonorgestrel and ethinyl estradiol and their combination on
biotransformation reactions]. In German. Zentralbl Gynäkol 1991;112:735-46.
Balogh A, Klinger G, Henschel L, Börner A, Vollanth R, Kuhnz W. Influence of
ethinylestradiol-containing combination oral contraceptives with gestodene or
levonorgestrel on caffeine elimination. Eur J Clin Pharmacol 1995;48:161-6.
Batty KT, Davis TM, Ilett KF, Dusci LJ, Langton SR. The effect of ciprofloxacin on
theophylline pharmacokinetics in healthy subjects. Br J Clin Pharmacol 1995;39:305-11.
Becquemont L, Ragueneau I, Le Bot MA, Riche C, Funck-Brentano C, Jaillon P.
Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans.
Clin Pharm Ther 1997;61:619-27.
Becquemont L, Mouajjah S, Escaffre O, Beaune P, Funck-Brentano C, Jaillon P.
Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab
Dispos 1999;27:1068-73.
Belle DJ, Callaghan JT, Gorski JC, Maya JF, Mousa O, Wrighton SA, Hall SD. The
effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A
activity. Br J Clin Pharmacol 2002;53:67-74.
Belpaire FM, Wijnant P, Temmerman A, Rasmussen BB, Brøsen K. The oxidative
metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin
reuptake inhibitors. Eur J Clin Pharmacol 1998;54:261-4.
Bertilsson L, Carrillo JA, Dahl ML, Llerena A, Alm C, Bondesson U, Lindström L,
Rodriguez de la Rubia I, Ramos S, Benitez J. Clozapine disposition covaries with
CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994;38:471-3.
Bertino J Jr, Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000;22:798-
817.
Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of
metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-58.
Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P, Eap CB. Increased clozapine
plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2
genotyped patients. Ther Drug Monit 2005;27:539-43.
Breen KJ, Bury RW, Calder IV, Desmond PV, Peters M, Mashford ML. A
[14C]phenacetin breath test to measure hepatic function in man. Hepatology 1984;4:47-52.
References
66
Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of
desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin
Pharmacol 1993a;44:349-55.
Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent
inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993b;45:1211-4.
Brouwers JR. Drug interactions with quinolone antibacterials. Drug Saf 1992;7:268-81.
Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P-450PA (P-
450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-
demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci
USA 1989;86:7696-700.
Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and
pharmacodynamic profile. Clin Pharmacokinet 1999;37:177-93.
Carrillo JA, Dahl ML, Svensson JO, Alm C, Rodriguez I, Bertilsson L. Disposition of
fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the
CYP1A2 activity. Clin Pharmacol Ther 1996;60:183-90.
Carrillo JA, Benitez J. Clinically significant pharmacokinetic interactions between
dietary caffeine and medications. Clin Pharmacokinet 2000;39:127-53.
Chang W-H, Augustin B, Lane H-Y, Zumbrunnen T, Liu H-C, Kazmi Y, Jann MW.
In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and
clozapine. Psychopharmacology 1999;145:91-8.
Chauret N, Gauthier A, Nicoll-Griffith DA. Effect of common organic solvents on in
vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug
Metab Dispos 1998;26:1-4.
Chida M, Yokoi T, Fukui T, Kinoshita M, Yokota J, Kamataki T. Detection of three
genetic polymorphisms in the 5'-flanking region and intron 1 of human CYP1A2 in the
Japanese population. Jpn J Cancer Res 1999;90:899-902.
Chou FC, Tzeng SJ, Huang JD. Genetic polymorphism of cytochrome P450 3A5 in
Chinese. Drug Metab Dispos 2001;29:1205-9.
Christensen M, Tybring G, Mihara K, Yasui-Furokori N, Carrillo JA, Ramos SI,
Andersson K, Dahl ML, Bertilsson L. Low daily 10-mg and 20-mg doses of fluvoxamine
inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole
(cytochrome P4502C19). Clin Pharm Ther 2002;71:141-52.
Court MH, Duan SX, Hesse LM, Venkatakrishnan K, Greenblatt DJ. Cytochrome P-
450 2B6 is responsible for interindividual variability of propofol hydroxylation by human
liver microsomes. Anesthesiology 2001;94:110-9.
References
67
Coward DM. Tizanidine: Neuropharmacology and mechanism of action. Neurology
1994;44S9:S6-S11.
Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam
Clin Pharmacol 2003;17:27-41.
Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm
Res 1993;10:1093-5.
Davies J. Selective depression of synaptic transmission of spinal neurones in the cat by a
new centrally acting muscle relaxant, 5-chloro-4-(2-imidazolin-2-yl-amino)-2, 1, 3-
benzothiodazole (DS103-282). Br J Pharmacol 1982;76:473-81.
Davis R, Markham A, Balfour JA. Ciprofloxacin. An updated review of its
pharmacology, therapeutic efficacy and tolerability. Drugs 1996;51:1019-74.
Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic
metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal
tracts. Annu Rev Pharmacol Toxicol 2003;43:149-73.
Dollery C. Therapeutic drugs. 2nd ed. Edinburgh (United Kingdom): Churchill
Livingstone; 1999.
Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger
K. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic
CYP3A4. Clin Pharmacol Ther 2000;68:598-604.
Eagling VA, Tjia JF, Back DJ. Differential selectivity of cytochrome P450 inhibitors
against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol
1998;45:107-14.
Easterbrook J, Lu C, Sakai Y, Li AP. Effects of organic solvents on the activities of
cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol
sulfotransferase in human hepatocytes. Drug Metab Dispos 2001;29:141-4.
Emre M, Leslie GC, Muir C, Part NJ, Pokorny R, Roberts RC. Correlations between
dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud). J Neurol
Neurosurg Psychiatry 1994;57:1355-9.
Emre M. The gastroprotective effects of tizanidine: an overview. Current Therapeutic
Research. 1998;59:2-12.
Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in
vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human
hepatic cytochromes P-450. Drug Metab Dispos 1999;27:1488-95.
References
68
Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why,
how and when? Basic Clin Pharmacol 2005;97:125-34.
Facciola G, Hidestrand M, von Bahr C, Tybring G. Cytochrome P450 isoforms
involved in melatonin metabolism in human liver microsomes. Eur J Clin Pharmacol
2001;56:881-8.
Figgitt DP, McClellan KJ. Fluvoxamine. An updated review of its use in the management
of adults with anxiety disorders. Drugs 2000;60:925-54.
Finnish Statistics on Medicines 2004. Helsinki (Finland): National Agency for Medicines
and Social Insurance Institution. 2005.
Freitag FG. Preventative treatment for migraine and tension-type headaches : do drugs
having effects on muscle spasm and tone have a role? CNS Drugs 2003;17:373-81.
Fromm MF, Kroemer HK, Eichelbaum M. Impact of P450 genetic polymorphism on the
first-pass extraction of cardiovascular and neuroactive drugs. Adv Drug Deliv Rev
1997;27:171-199.
Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-
glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction
between digoxin and quinidine. Circulation 1999;99:552-7.
Fuhr U, Wolff T, Harder S, Schymanski P, Staib AH. Quinolone inhibition of
cytochrome P-450-dependent caffeine metabolism in human liver microsomes. Drug
Metab Dispos 1990;18:1005-10.
Fuhr U, Anders EM, Mahr G, Sorgel F, Staib AH. Inhibitory potency of quinolone
antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob
Agents Chemother 1992;36:942-8.
Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine
ratio in plasma and saliva. Pharmacogenetics 1994;4:109-116.
Fuhr U, Rost KL, Engelhardt R, Sachs M, Liermann D, Belloc C, Beaune P, Janezic
S, Grant D, Meyer UA, Staib AH. Evaluation of caffeine as a test drug for CYP1A2,
NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.
Pharmacogenetics 1996;6:159-76.
Fuhr U. Induction of drug metabolising enzymes: pharmacokinetic and toxicological
consequences in humans. Clin Pharmacokinet 2000;38:493-504.
Fuhr U, Kober S, Zaigler M, Mutschler E, Spahn-Langguth H. Rate-limiting
biotransformation of triamterene is mediated by CYP1A2. Int J Clin Pharmacol Ther
2005;43:327-34.
References
69
Furuta T, Ohashi K, Kobayashi K, Iida I, Yoshida H, Shirai N, Takashima M,
Kosuge K, Hanai H, Chiba K, Ishizaki T, Kaneko E. Effects of clarithromycin on the
metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin
Pharmacol Ther 1999;66:265-74.
Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of
CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug
Metab Pharmacokinet 2005;20:153-67.
Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM,
Carrere N, Maurel P. Induction of CYP2C genes in human hepatocytes in primary
culture. Drug Metab Dispos 2001;29:242-51.
Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V,
Martin H, Beaune P, de Waziers I. Human CYP2B6: expression, inducibility and
catalytic activities. Pharmacogenetics 1999;9:295-306.
Geyskes GG, Boer P, Dorhout Mees EJ. Clonidine withdrawal. Mechanism and
frequency of rebound hypertension. Br J Clin Pharmacol 1979;7:55-62.
Gibson GG, Skett P. Induction and inhibition of drug metabolism. In: Introduction to drug
metabolism. 3rd ed. Cheltenham: Nelson Thornes Ltd; 2001:87-118.
Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C
subfamily. Br J Clin Pharmacol 2001;52:349-55.
Guengerich FP. Mechanism-based inactivation of human liver microsomal cytochrome P-
450 IIIA4 by gestodene. Chem Res Toxicol 1990a;3:363-71.
Guengerich FP. Inhibition of oral contraceptive steroid-metabolizing enzymes by steroids
and drugs. Am J Obstet Gynecol 1990b;163:2159-63.
Hammond GL, Bocchinfuso WP, Orava M, Smith CL, van den Ende A, van Enk A.
Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene.
Contraception 1994;50:301-18.
Harder S, Staib AH, Beer C, Papenburg A, Stille W, Shah PM. 4-Quinolones inhibit
biotransformation of caffeine. Eur J Clin Pharmacol 1988;35:651-6.
Harris RZ, Jang GR, Tsunoda S. Dietary effects on drug metabolism and transport. Clin
Pharmacokinet 2003;42:1071-88.
Heazlewood V, Symoniw P, Maruff P, Eadie MJ. Tizanidine--initial pharmacokinetic
studies in patients with spasticity. Eur J Clin Pharmacol 1983;25:65-7.
Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450
mediated drug-drug interactions: an update. Curr Drug Metab 2002;3:13-37.
References
70
Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ,
Lindemans J, Weimar W, van Gelder T. Genetic polymorphisms of the CYP3A4,
CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors
cyclosporine and tacrolimus. Clin Pharmacol Ther 2003;74:245-54.
Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI,
Greenblatt DJ. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug
interactions with other antidepressants. Drug Metab Dispos 2000;28:1176-83.
Hickman D, Wang JP, Wang Y, Unadkat JD. Evaluation of the selectivity of In vitro
probes and suitability of organic solvents for the measurement of human cytochrome P450
monooxygenase activities. Drug Metab Dispos 1998;26:207-15.
Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-
demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2002;30:853-
8.
Holland DT, Godfredsen KA, Page T, Connor JD. Simple high-performance liquid
chromatography method for the simultaneous determination of serum caffeine and
paraxanthine following rapid sample preparation. J Chromatogr B Biomed Sci Appl
1998;707:105-10.
Honda M, Sekiguchi Y, Sato N, Ono H. Involvement of imidazoline receptors in the
centrally acting muscle-relaxant effects of tizanidine. Eur J Pharmacol 2002;445:187-93.
Hägg S, Spigset O, Dahlqvist R. Influence of gender and oral contraceptives on CYP2D6
and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 2001;51:169-73.
Härtter S, Ursing C, Morita S, Tybring G, von Bahr C, Christensen M, Rojdmark S,
Bertilsson L. Orally given melatonin may serve as a probe drug for cytochrome P450 1A2
activity in vivo: a pilot study. Clin Pharmacol Ther 2001;70:10-6.
Härtter S, Nordmark A, Rose DM, Bertilsson L, Tybring G, Laine K. Effects of
caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity.
Br J Clin Pharmacol 2003;56:679-82.
Iwatsubo T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Yokoi
T, Kamataki T, Sugiyama Y. Prediction of in vivo hepatic metabolic clearance of YM796
from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. J
Pharmacol Exp Ther 1997;282:909-19.
Jain NK, Kulkarni SK, Singh A. Modulation of NSAID-induced antinociceptive and
anti-inflammatory effects by alpha2-adrenoceptor agonists with gastroprotective effects.
Life Sci 2002;70:2857-69.
References
71
Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K. Dose-dependent
inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine
and paroxetine. Eur J Clin Pharmacol 1996;51:73-8.
Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M.
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause
of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993;90:11825-9.
Jokinen MJ, Ahonen J, Neuvonen PJ, Olkkola KT. The effect of erythromycin,
fluvoxamine, and their combination on the pharmacokinetics of ropivacaine. Anesth Analg
2000;91:1207-12.
Jokinen MJ, Olkkola KT, Ahonen J, Neuvonen PJ. Effect of ciprofloxacin on the
pharmacokinetics of ropivacaine. Eur J Clin Pharmacol 2003;58:653-7.
Jung-Hoffmann C, Kuhl H. Pharmacokinetics and pharmacodynamics of oral
contraceptive steroids: Factors influencing steroid metabolism. Am J Obstet Gynecol
1990;2183-97.
Kaplan B. Desogestrel, norgestimate, and gestodene: the newer progestins. Ann
Pharmacother 1995;29:736-42.
Kent UM, Mills DE, Rajnarayanan RV, Alworth WL, Hollenberg PF. Effect of 17-?-
ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization
of inactivation of P450s 2B1 and 2B6 and identification of metabolites. J Pharmacol Exp
Ther 2002;300:549-58.
Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM,
Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR. Interrelationship
between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res
1999;16:408-14.
Kinirons MT, Crome P. Clinical pharmacokinetic considerations in the elderly. An
update. Clin Pharmacokinet 1997;33:302-12.
Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Murdter TE, Roots I,
Brockmoller J. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic
polymorphisms in CYP2B6. Pharmacogenetics 2003;13:619-26.
Kivistö KT, Brookjans G, Fromm MF, Griese EU, Münzel P, Kroemer HK.
Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br J Clin
Pharmacol 1996;42:387-9.
Kivistö KT, Wang JS, Backman JT, Nyman L, Taavitsainen P, Anttila M, Neuvonen
PJ. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. Eur
J Clin Pharmacol 2001;57:37-42.
References
72
Kivistö KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF, Schwab M,
Eichelbaum M, Strandberg T. Lipid-lowering response to statins is affected by CYP3A5
polymorphism. Pharmacogenetics 2004;14:523-5.
Klotz U, Ammon E. Clinical and toxicological consequences of the inductive potential of
ethanol. Eur J Clin Pharmacol 1998;54:7-12.
Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors.
Basic Clin Pharmacol Toxicol 2004;95:2-8.
Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, Nuessler A, Neuhaus
P, Eichelbaum M, Zanger U, Wojnowski L. Interindividual variability and tissue-
specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos
2002;30:1108-14.
Koch P, Hirst DR, von Wartburg BR. Biological fate of sirdalud in animals and man.
Xenobiotica 1989;19:1255-65.
Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and
lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997;25:853-
62.
Kootstra-Ros JE, Smallegoor W, van der Weide J. The cytochrome P450 CYP1A2
genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of
schizophrenic patients. Ann Clin Biochem 2005;42:216-9.
Krishna D, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet
1994;26:144-60.
Kroboth PD, Smith RB, Stoehr GP, Juhl RP. Pharmacodynamic evaluation of the
benzodiazepine-oral contraceptive interaction. Clin Pharmacol Ther 1985;38:525-32.
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A,
Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan
R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A
promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.
Nat Genet 2001;27:383-91.
Kunze KL, Trager WF. Isoform-selective mechanism-based inhibition of human
cytochrome P450 1A2 by furafylline. Chem Res Toxicol 1993;6:649-56.
Kusuhara H, Sugiyama Y. Drug-drug interactions involving the membrane transport
process. In: Rodrigues AD, ed. Drug-drug interactions. New York, NY, USA: Marcel
Dekker; 2002:123-88.
References
73
Laine K, Anttila M, Helminen A, Karnani H, Huupponen R. Dose linearity study of
selegiline pharmacokinetics after oral administration: evidence for strong drug interaction
with female sex steroids. Br J Clin Pharmacol 1999;47:249-54.
Laine K, Tybring G, Bertilsson L. No sex-related differences but significant inhibition by
oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and
omeprazole in healthy Swedish white subjects. Clin Pharmacol Ther 2000;68:151-9.
Laine K, Yasar U, Widén J, Tybring G. A screening study on the liability of eight
different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver
microsomes. Pharmacol Toxicol 2003;93:77-81.
Lake AE 3rd, Saper JR. Chronic headache: New advances in treatment strategies.
Neurology 2002;59(Suppl 2):S8-S13.
Lake BG. Preparation and characterisation of microsomal fractions for studies on
xenobiotic metabolism. In: Snell K, Mullock B, eds. Biochemical Toxicology: A practical
approach. Oxford, UK: IRL Press, 1987;183-215.
Lamberg TS, Kivistö KT, Laitila J, Martensson K, Neuvonen PJ. The effect of
fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone. Eur J Clin
Pharmacol 1998;54:761-6.
Larsen JT,  Brøsen K. Consumption of charcoal-broiled meat as an experimental tool for
discerning CYP1A2-mediated drug metabolism in vivo. Basic Clin Pharmacol Toxicol
2005;97:141-8.
Lataste X, Emre M, Davis C, Groves L. Comparative profile of tizanidine in the
management of spasticity. Neurology 1994;44(Suppl 9):S53-9.
Lee J, Seo JH, Kim DH. Determination of tizanidine in human plasma by gas
chromatography-mass spectrometry. Analyst 2002;127:917-20.
Lehto P, Kivistö KT, Neuvonen PJ. The effect of ferrous sulphate on the absorption of
norfloxacin, ciprofloxacin and ofloxacin. Br J Clin Pharmacol 1994;37:82-5.
Lelo A, Birkett DJ, Robson RA, Miners JO. Comparative pharmacokinetics of caffeine
and its primary demethylated metabolites paraxanthine, theobromine and theophylline in
man. Br J Clin Pharmacol 1986;22:177-82.
Lin HL, Kent UM, Hollenberg PF. Mechanism-based inactivation of cytochrome P450
3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to
protein. J Pharmacol Exp Ther 2002;301:160-7.
Lin JH, Lu AY. Role of pharmacokinetics and metabolism in drug discovery and
development. Pharmacol Rev 1997;49:403-49.
References
74
Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical
implications. Clin Pharmacokinet 1998;35:361-90.
Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications.
Clin Pharmacokinet 2003;42:59-98.
Lo A, Burckart GJ. P-glycoprotein and drug therapy in organ transplantation. J Clin
Pharmacol 1999;39:995-1005.
Madden S, Woolf TF, Pool WF, Park BK. An investigation into the formation of stable,
protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat
liver microsomes. Biochem Pharmacol 1993;46:13-20.
Maeda-Hagiwara M, Watanabe H, Kanaoka R, Watanabe K. Reduction of centrally-
stimulated gastric acid secretion by tizanidine, a new imidazoline derivative, in
anesthetized rats. Arch Int Pharmacodyn Ther 1985;277:321-7.
Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of
Debrisoquine in man. Lancet 1977 Sep 17;2(8038):584-6.
Mathias CJ, Luckitt J, Desai P, Baker H, el Masri W, Frankel HL. Pharmacodynamics
and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord
injury. J Rehabil Res Dev 1989;26:9-16.
Maya MT, Goncalves NJ, Silva NB, Morais JA. Simple high-performance liquid
chromatographic assay for the determination of ciprofloxacin in human plasma with
ultraviolet detection. J Chromatogr B Biomed Sci Appl 2001;755:305-9.
Meibohm B, Beierle I, Derendorf H. How important are gender differences in
pharmacokinetics? Clin Pharmacokinet 2002;41:329-42.
Meyer UA. Overview of enzymes of drug metabolism. J Pharmacokinet Biopharm
1996;24:449-59.
Miettinen TJ, Kanto JH, Salonen MA, Scheinin M. The sedative and sympatholytic
effects of oral tizanidine in healthy volunteers. Anesth Analg 1996;82:817-20.
Mimura M, Baba T, Yamazaki H, Ohmori S, Inui Y, Gonzalez FJ, Guengerich FP,
Shimada T. Characterization of cytochrome P-450 2B6 in human liver microsomes. Drug
Metab Dispos 1993;21:1048-56.
Miners JO, McKinnon RA. CYP1A. In: Levy RH, Thummel KE, Trager WF, Hansten
PD, Eichelbaum M, eds. Metabolic drug interactions. Philadelphia, PA, USA: Lippincott
Williams & Wilkins; 2000:61-73.
Momo K, Doki K, Hosono H, Homma M, Kohda Y. Drug interaction of tizanidine and
fluvoxamine. Clin Pharmacol Ther 2004;76:509-10.
References
75
Muramatsu I, Kigoshi S. Tizanidine may discriminate between imidazoline-receptors and
alpha 2-adrenoceptors. Jpn J Pharmacol 1992 Aug;59(4):457-9.
Murros K, Kataja M, Hedman C, Havanka H, Sako E, Färkkilä M, Peltola J,
Keränen T. Modified-release formulation of tizanidine in chronic tension-type headache.
Headache 2000;40:633-7.
Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic
polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2
inducibility in humans. J Biochem (Tokyo) 1999;125:803-8.
Nance PW, Sheremata WA, Lynch SG, Vollmer T, Hudson S, Francis GS, O'Connor
P, Cohen JA, Schapiro RT, Whitham R, Mass MK, Lindsey JW, Shellenberger K.
Relationship of the antispasticity effect of tizanidine to plasma concentration in patients
with multiple sclerosis. Arch Neurol 1997;54:731-6.
Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y. Prediction
of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies
with liver microsomes from animals and humans. Drug Metab Dispos 2001;29:1316-24.
Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet
2002;360:1152-62.
Neuvonen PJ, Kivistö KT, Lehto P. Interference of dairy products with the absorption of
ciprofloxacin. Clin Pharmacol Ther 1991;50:498-502.
Newton DJ, Wang RW, Lu AY. Cytochrome P450 inhibitors. Evaluation of specificities
in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab
Dispos 1995;23:154-8.
Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivistö KT. Effects of
fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of
glimepiride. Clin Pharmacol Ther 2001;69:194-200.
Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil,
itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of
repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.
Diabetologia 2003a;46:347-51.
Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, Neuvonen PJ.
Gemfibrozil considerably increases the plasma concentrations of rosiglitazone.
Diabetologia 2003b;46:1319-23.
Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic
interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003c;42:819-50.
References
76
Nordmark A, Lundgren S, Ask B, Granath F, Rane A. The effect of the CYP1A2 *1F
mutation on CYP1A2 inducibility in pregnant women. Br J Clin Pharmacol 2002;54:504-
10.
Oda Y, Furuichi K, Tanaka K, Hiroi T, Imaoka S, Asada A, Fujimori M, Funae Y.
Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450.
Anesthesiology 1995;82:214-20.
Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients
receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther
1994;55:481-5.
Omura T, Sato R. A new cytochrome in liver microsomes. J Biol Chem 1962;237:1375-6.
Orme ML, Back DJ, Breckenridge AM. Clinical pharmacokinetics of oral contraceptive
steroids. Clin Pharmacokinet 1983;8:95-136.
Ozono S, Yamaguchi A, Mochizuki H, Kawakami T, Fujimoto K, Otani T, Yoshida
K, Ichinei M, Yamashita T, Hirao Y. Caffeine test in predicting flutamide-induced
hepatic injury in patients with prostate cancer. Prostate Cancer Prostatic Dis 2002;5:128-
31.
Palego L, Marazziti D, Biondi L, Giannaccini G, Sarno N, Armani A, Lucacchini A,
Cassano GB, Dell'Osso L. Simultaneous plasma level analysis of clomipramine, N-
desmethylclomipramine, and fluvoxamine by reversed-phase liquid chromatography. Ther
Drug Monit 2000;22:190-4.
Palovaara S, Pelkonen O, Uusitalo J, Lundgren S, Laine K. Inhibition of cytochrome
P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by
bupropion hydroxylation. Clin Pharm Ther 2003;74:326-33.
Parker AC, Pritchard P, Preston T, Choonara I. Induction of CYP1A2 activity by
carbamazepine in children using the caffeine breath test. Br J Clin Pharmacol 1998;45:176-
8.
Partanen J, Jalava KM, Neuvonen PJ. Itraconazole increases serum digoxin
concentration. Pharmacol Toxicol 1996;79:274-6.
Pazzucconi F, Malavasi B, Galli G, Franceschini G, Calabresi L, Sirtori CR. Inhibition
of antipyrine metabolism by low-dose contraceptives with gestodene and desogestrel. Clin
Pharmacol Ther 1991;49:278-84.
Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A, Raunio H. Inhibition and induction
of human cytochrome P450 (CYP) enzymes. Xenobiotica 1998;28:1203-53.
Perucca E, Gatti G, Spina E. Clinical pharmacokinetics of fluvoxamine. Clin
Pharmacokinet 1994;27:175-90.
References
77
Pickard CE, Stewart AD, Hartley R, Lucock MD. A rapid HPLC method for monitoring
plasma levels of caffeine and theophylline using solid phase extraction columns. Ann Clin
Biochem 1986;23:440-6.
Proctor NJ, Tucker GT, Rostami-Hodjegan A. Predicting drug clearance from
recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica
2004;34:151-78.
Raaska K, Neuvonen PJ. Ciprofloxacin increases serum clozapine and N-
desmethylclozapine: a study in patients with schizophrenia. Eur J Clin Pharmacol
2000;56:585-9.
Raaska K, Raitasuo V, Laitila J, Neuvonen PJ. Effect of caffeine-containing versus
decaffeinated coffee on serum clozapine concentrations in hospitalised patients. Basic Clin
Pharmacol Toxicol 2004;94:13-8.
Rasmussen BB,  Brøsen K. Theophylline has no advantages over caffeine as a putative
model drug for assessing CYPIA2 activity in humans. Br J Clin Pharmacol 1997;43:253-8.
Rasmussen BB, Nielsen TL,  Brøsen K. Fluvoxamine is a potent inhibitor of the
metabolism of caffeine in vitro. Pharmacol Toxicol 1998;83:240-5.
Rasmussen BB, Brix TH, Kyvik KO, Brøsen K. The interindividual differences in the 3-
demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental
factors. Pharmacogenetics 2002;12:473-8.
Raucy J, Carpenter SP. CYP2E. In: Levy RH, Thummel KE, Trager WF, Hansten PD,
Eichelbaum M, eds. Metabolic drug interactions. Philadelphia, PA, USA: Lippincott
Williams & Wilkins; 2000:95-113.
Rettie AE, Koop D, Haining RL. CYP2C. In: Levy RH, Thummel KE, Trager WF,
Hansten PD, Eichelbaum M, eds. Metabolic drug interactions. Philadelphia, PA, USA:
Lippincott Williams & Wilkins; 2000:75-86.
Rietveld EC, Broekman MMM, Houben JJG, Eskes TKAB, van Rossum JM. Rapid
onset of an increase in caffeine residence time in young women due to oral contraceptive
steroids. Eur J Clin Pharmacol 1984;26:371-3.
Ring BJ, Wrighton SA. Industrial viewpoint: application of in vitro drug metabolism in
various phases of drug development. In: Levy RH, Thummel KE, Trager WF, Hansten PD,
Eichelbaum M, eds. Metabolic drug interactions. Philadelphia, PA, USA: Lippincott
Williams & Wilkins; 2000:29-39.
Roberts RC, Part NJ, Pokorny R, Muir C, Leslie GC, Emre M. Pharmacokinetics and
pharmacodynamics of tizanidine. Neurology 1994;44(Suppl 9):S29-31.
References
78
Roberts RK, Grice J, McGuffie C, Heilbronn L. Oral contraceptive steroids impair the
elimination of theophylline. J Lab Clin Med 1983;101:821-5.
Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C-->A
polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J
Clin Pharmacol 1999;47:445-9.
Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K. Influence of usual intake of
dietary caffeine on single-dose kinetics of theophylline in healthy human subjects. Eur J
Clin Pharmacol 1993;44:295-8.
Scavone JM, Greenblatt DJ, Locniskar A, Shader RI. Alprazolam pharmacokinetics in
women on low-dose oral contraceptives. J Clin Pharmacol 1988;28:454-7.
Schulze TG, Schumacher J, Muller DJ, Krauss H, Alfter D, Maroldt A, Ahle G,
Maroldt AO, Novo y Fernandez A, Weber T, Held T, Propping P, Maier W, Nothen
MM, Rietschel M. Lack of association between a functional polymorphism of the
cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am J Med
Genet 2001;105:498-501.
Shellenberger MK, Groves L, Shah J, Novack GD. A controlled pharmacokinetic
evaluation of tizanidine and baclofen at steady state. Drug Metab Dispos 1999;27:201-4.
Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual
variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs,
carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30
Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
Shimoda K, Someya T, Morita S, Hirokane G, Yokono A, Takahashi S, Okawa M.
Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in
intron 1 and G/A polymorphism at position -2964 in the 5'-flanking region of CYP1A2) on
the plasma concentration of haloperidol in smoking male Japanese with schizophrenia.
Prog Neuropsychopharmacol Biol Psychiatry 2002;26:261-5.
Silverman JA. P-glycoprotein. In: Levy RH, Thummel KE, Trager WF, Hansten PD,
Eichelbaum M, eds. Metabolic drug interactions. Philadelphia, PA, USA: Lippincott
Williams & Wilkins; 2000:135-144.
Slayter KL, Ludwig EA, Lew KH, Middleton E Jr, Ferry JJ, Jusko WJ. Oral
contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics.
Clin Pharmacol Ther 1996;59:312-21.
Smith C, Birnbaum G, Carter JL, Greenstein J, Lublin FD. Tizanidine treatment of
spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial.
US Tizanidine Study Group. Neurology 1994;44(Suppl 9):S34-43.
References
79
Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked
drug metabolism in humans: an analysis of 226 subjects with equal histopathologic
conditions. Clin Pharmacol Ther 1997;61:331-9.
Spaldin V, Madden S, Pool WF, Woolf TF, Park BK. The effect of enzyme inhibition
on the metabolism and activation of tacrine by human liver microsomes. Br J Clin
Pharmacol 1994;38:15-22.
Stahlmann R, Lode H. Fluoroquinolones in the elderly: safety considerations. Drugs
Aging 2003;20:289-302.
Stoehr GP, Kroboth PD, Juhl RP, Wender DB, Phillips JP, Smith RB. Effect of oral
contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clin
Pharmacol Ther 1984;36:683-90.
Stone BM. Pencil and paper tests--sensitivity to psychotropic drugs. Br J Clin Pharmacol
1984;18(Suppl 1):S15-20.
Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R. Effect of cigarette smoking on
fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 1995;58:399-403.
Spigset O, Hägg S, Söderström E, Dahlqvist R. The paraxanthine:caffeine ratio in serum
or in saliva as a measure of CYP1A2 activity: when should the sample be obtained?
Pharmacogenetics 1999;9:409-12.
Taittonen M, Raty H, Kirvela O, Aantaa R, Kanto J. The metabolic effects of oral
tizanidine in healthy volunteers. Acta Anaesthesiol Scand 1995;39:628-32.
Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance.
J Clin Pharm Ther 1999;24:339-46.
Tantcheva-Poor I, Zaigler M, Rietbrock S, Fuhr U. Estimation of cytochrome P-450
CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test.
Pharmacogenetics 1999;9:131-44.
Tateishi T, Watanabe M, Moriya H, Yamaguchi S, Sato T, Kobayashi S. No ethnic
difference between Caucasian and Japanese hepatic samples in the expression frequency of
CYP3A5 and CYP3A7 proteins. Biochem Pharmacol 1999;57:935-9.
Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human
CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389-430.
Tjia JF, Colbert J, Back DJ. Theophylline metabolism in human liver microsomes:
inhibition studies. J Pharmacol Exp Ther 1996;276:912-7.
References
80
Tornatore KM, Kanarkowski R, McCarthy TL, Gardner MJ, Yurchak AM, Jusko
WJ. Effect of chronic oral contraceptive steroids on theophylline disposition. Eur J Clin
Pharmacol 1982;23:129-34.
Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and
regulation. Physiol Rev 2003;83:633-71.
Tse FLS, Jaffe JM, Bhuta S. Pharmacokinetics of orally administered tizanidine in
healthy volunteers. Fundam Clin Pharmacol 1987;1:479-88.
Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K. Effect of
clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion
hydroxylation. Clin Pharmacol Ther 2005;77:553-9.
Täuber U, Kuhnz W, Humpel M. Pharmacokinetics of gestodene and ethinyl estradiol
after oral administration of a monophasic contraceptive. Am J Obstet Gynecol
1990;163:1414-20.
the United Kingdom Tizanidine Trial Group. A double-blind, placebo-controlled trial of
tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology
1994;44(Suppl 9):S70-8.
Van Vleet TR, Bombick DW, Coulombe RA Jr. Inhibition of human cytochrome P450
2E1 by nicotine, cotinine, and aqueous cigarette tar extract in vitro. Toxicol Sci
2001;64:185-91.
Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Human drug metabolism and the
cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol
2001;41:1149-79.
von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS,
Shader RI. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by
fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996;36:783-
91.
Wagstaff AJ, Bryson HM. Tizanidine: a review of its pharmacology, clinical efficacy,
and tolerability in the management of spasticity associated with cerebral, and spinal
disorders. Drugs 1997;53:435-52.
Wallace JD. Summary of combined clinical analysis of controlled clinical trials with
tizanidine. Neurology 1994;44(Suppl 9):S60-9.
Walsky RL, Obach RS, Gaman EA, Gleeson JP, Proctor WR. Selective inhibition of
human cytochrome P4502C8 by montelukast. Drug Metab Dispos 2005;33:413-8.
Wang B, Sanchez RI, Franklin RB, Evans DC, Huskey SE. The involvement of
CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos
References
81
2004;32:1209-12.
Wang JS, Backman JT, Taavitsainen P, Neuvonen PJ, Kivistö KT. Involvement of
CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug
Metab Dispos 2000;28:959-65.
Wang JS, Neuvonen M, Wen X, Backman JT, Neuvonen PJ. Gemfibrozil inhibits
CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab
Dispos 2002;30:1352-6.
Ward S, Back DJ. Metabolism of gestodene in human liver cytosol and microsomes in
vitro. J Steroid Biochem Mol Biol 1993;46:235-43.
Wen X, Wang JS, Backman JT, Laitila J, Neuvonen PJ. Trimethoprim and
sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug
Metab Dispos 2002;30:631-5.
Wijnands WJ, Vree TB, van Herwaarden CL. The influence of quinolone derivatives on
theophylline clearance. Br J Clin Pharmacol 1986;22:677-83.
Wilde MI, Balfour JA. Gestodene. A review of its pharmacology, efficacy and tolerability
in combined contraceptive preparations. Drugs 1995;50:364-95.
Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev 1987;39:1-47.
Wrighton SA, Molowa DT, Guzelian PS. Identification of a cytochrome P-450 in human
fetal liver related to glucocorticoid-inducible cytochrome P-450HLp in the adult. Biochem
Pharmacol 1988;37:3053-5.
Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa
DT, Vandenbranden M. Studies on the expression and metabolic capabilities of human
liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990;38:207-13.
Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug
metabolism. Crit Rev Toxicol 1992;22:1-21.
Wrighton SA, Thummel KE. CYP3A. In: Levy RH, Thummel KE, Trager WF, Hansten
PD, Eichelbaum M, eds. Metabolic drug interactions. Philadelphia, PA, USA: Lippincott
Williams & Wilkins; 2000:87-94.
Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, Rane A. Role of
polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J
2003;3:53-61.
Yao C, Kunze KL, Kharasch ED, Wang Y, Trager WF, Ragueneau I, Levy RH.
Fluvoxamine-theophylline interaction: Gap between in vitro and in vivo inhibition
constants toward cytochrome P4501A2. Clin Pharmacol Ther 2001;70:415-24.
References
82
Yu BN, Chen GL, He N, Ouyang DS, Chen XP, Liu ZQ, Zhou HH. Pharmacokinetics
of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos
2003;31:1255-9.
Yu KS, Cho JY, Shon JH, Bae KS, Yi SY, Lim HS, Jang IJ, Shin SG. Ethnic
differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin.
Clin Pharmacol Ther 2001;70:228-36.
Zanaflex product information. Available from: URL: http://www.fda.gov/cder/foi
/label/2002/21447lbl.pdf. and www.drugs.com/PDR/Zanaflex_Tablets.html Accessed
October 9, 2005.
Zanger UM, Eichelbaum M. CYP2D6. In: Levy RH, Thummel KE, Trager WF, Hansten
PD, Eichelbaum M, eds. Metabolic drug interactions. Philadelphia, PA, USA: Lippincott
Williams & Wilkins; 2000:87-94.
Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS.
Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos
1999;27:804-9.
